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Zusammenfassung 
 
Gegenstand aktueller Debatten ist häufig die Frage, zu welchem Ausmass verschiedene 
Domänen der menschlichen Kognition, wie zum Beispiel das Gedächtnis, von unseren Genen 
und/oder von unserer Umwelt beeinflusst werden. In Zwillingsstudien konnte eine ungefähre 
Heritabilität von 50% festgelegt werden. Somit wurde aufgezeigt, dass natürlich auftretende 
genetische Variationen einen wichtigen Einfluss auf die interindividuelle Variabilität in den 
Gedächtnisleistungen ausüben. In dieser Doktorarbeit wurden genetische Analysen, die 
funktionelle und strukturelle Bildgebung des Gehirns und quantitative neuropsychologische 
Methoden kombiniert, um den Einfluss der beiden Gene Apolipoprotein E (APOE) und 
Presenilin 1 (PSEN1) auf die normalen Gedächtnisleistungen, auf gedächtnisbezogene 
Hirnaktivierungen und auf die Neuroanatomie zu untersuchen.  
 
In der ersten Studie versuchten wir herauszufinden, ob der APOE Genotyp eine Rolle in der 
normalen Gedächtnisfunktion spielt. Das APOE Gen hat drei Allelvarianten: ε2, ε3 und ε4. 
Das ε4 Allel erhöht das Risiko an der sporadischen Form der Alzheimer Demenz (AD) mit 
spätem Beginn zu erkranken. In Personen mittleren Alters und in älteren Personen wurde 
gezeigt, dass das ε4 Allel schädliche Auswirkungen auf kognitive Leistungen, auf die 
gedächtnisbezogene Hirnaktivität und auf den Glukose Metabolismus des Gehirns ausüben 
kann. Bisher wurde jedoch in Unabhängigkeit der Alzheimer-bezogenen Pathologie kein 
Einfluss des ε4 Allels auf das normale Gedächtnis berichtet.  
In einer Stichprobe von 340 jungen und gesunden Personen fanden wir einen besseren 
episodischen Gedächtnisabruf in ε4 Allel Trägern, wenn diese mit ε2 oder ε3 Trägern 
verglichen wurden. Weiter untersuchten wir die Hirnaktivität und Hirnanatomie von 34 
Versuchspersonen mittels funktioneller und struktureller Magnet Resonanz Tomographie. 
Dabei konnte ein genetischer Effekt auf die gedächtnisbezogene Hirnaktivität gezeigt werden. 
In den ε4 Trägern nahm die Hirnaktivität in einem gedächtnisrelevanten Netzwerk während 
des wiederholten Lernens visueller Reize ab. Ausserdem wiesen die ε4 Träger eine reduzierte 
Hirnaktivität beim Erinnern der zuvor gelernten Reize auf. Die ε2 und ε3 Träger hingegen 
zeigten eine Aktivitätszunahme während des Lernens und eine erweiterte Aktivierung 
während des Erinnerns. Diese genotypinduzierten Hirnaktivierungsunterschiede traten auf, 
obwohl der APOE Genotyp keinen differentiellen Einfluss auf die neuropsychologischen 
Leistungen, die Hirnvolumina und die arbeitsgedächtnis- und aufmerksamkeitsbezogene 
Hirnaktivität hatte.  
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Unsere Resultate deuten darauf hin, dass das APOE ε4 Allel einen vorteilhaften Einfluss auf 
die Gedächtnisfunktionen im jungen Erwachsenenalter ausübt. Dies manifestiert sich in den 
jungen ε4 Trägern als ein besseres episodisches Gedächtnis und als ein sparsamer Gebrauch 
gedächtnisbezogener neuronaler Ressourcen.  
 
Die zweite Studie zielte darauf ab, frühe präklinische Merkmale der Alzheimer Demenz zu 
detektieren. Mutationen im PSEN1 Gen werden autosomal dominant an die Nachkommen 
weitergegeben, und führen zur familiären Form der Alzheimer Demenz (FAD). Diese ist, im 
Vergleich zur sporadischen AD, durch einen früheren Beginn und einen schnelleren 
Krankheitsverlauf charakterisiert. Wir untersuchten fünf nicht erkrankte Mitglieder einer 
Familie mit FAD. Ein junges Familienmitglied (20-jährig) und ein Familienmitglied mittleren 
Alters (45-jährig) trugen die C410Y Mutation im Presenilin1 Gen. In Familien mit dieser 
Mutation beginnt die Krankheit im Alter von etwa 48 Jahren.  
Beide Mutationsträger zeigten selektiv schlechtere Gedächtnisleistungen in episodischen 
Gedächtnisaufgaben. Ausserdem wurde im jungen Mutationsträger während des episodischen 
Lernens und Erinnerns eine erhöhte Hirnaktivität in einem gedächtnisbezogenen Netzwerk 
gefunden, wenn dieser mit 21 gesunden, jungen Kontrollprobanden und mit 
Familienmitgliedern ohne Mutation verglichen wurde. Im Gegensatz dazu, zeigte die 
Mutationsträgerin im mittleren Alter während des episodischen Lernens und Erinnerns eine 
verminderte Aktivität in gedächtnisbezogenen Hirnstrukturen.  
Die verstärkte Hirnaktivität im jungen Mutationsträger reflektiert mit hoher 
Wahrscheinlichkeit kompensatorische Mechanismen, welche Folge der zunehmenden, 
gedächtnisschädigenden AD Neuropathologie sind. Auf der anderen Seite reflektiert die 
reduzierte Hirnaktivität in der Mutationsträgerin mittleren Alters höchstwahrscheinlich eine 
substantielle neuronale Dysfunktion, welche auf die weiter fortgeschrittenen, 
neuropathologischen Ablagerungen zurückzuführen ist. Diese Daten zeigen, dass präklinische 
Gedächtnis Dysfunktionen, durch die Anwendung funktioneller Bildgebung und sensitiver 
Gedächtnistests, 30 Jahre vor dem klinischen Beginn der Krankheit erkannt werden können. 
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Summary 
 
There’s an ongoing debate about what extent nature and/or nurture influence human cognitive 
capacities like memory. Twin studies suggest a roughly 50% heritability estimate, indicating 
that naturally occurring genetic variations have an important impact on the interindividual 
variability in memory abilities. Genetic analyses, functional and structural magnetic 
resonance imaging, and quantitive neuropsychological methods were combined in this 
doctoral thesis to determine the influence of the apolipoprotein E (APOE) gene and the 
presenilin 1 (PSEN1) gene on normal memory performance, memory-related brain activity, 
and neuroanatomy. 
 
In the first study, we sought to learn, whether the APOE genotype plays a role in normal 
memory function. The APOE gene has three allelic variants; ε2, ε3, and ε4. The ε4 allele is 
associated with an increased risk of the development of sporadic late onset Alzheimer’s 
disease (AD), and detrimental effects of ε4 have been shown in middle-aged and elderly 
persons on cognition, memory-related brain activity, and brain glucose metabolism. As yet, an 
effect of ε4 on normal memory in absence of AD neuropathology is unknown.  
We found better episodic memory retrieval in ε4 allele carriers, as compared to the ε2 and ε3 
alleles, in a sample of 340 young, healthy persons. Using functional magnetic resonance 
imaging (fMRI) in a subset of 34 memory-matched subjects, we could show genetic effects on 
memory-related brain activity. Carriers of the ε4 allele decreased brain activity during the 
repeated learning of visual stimuli in a memory-related network and exhibited reduced 
retrieval-related activity. The ε2 and ε3 allele carriers, on the other hand, increased brain 
activity during repeated learning and exhibited enhanced retrieval-related activity. These 
genotype induced brain activity differences appeared although APOE isoforms had no 
differential effects on neuropsychological performance, brain volumes and brain activity 
related to working memory and attention.  
These results suggest a beneficial effect of the APOE ε4 allele in young adulthood, emerging 
as better episodic memory and an economic use of memory-related neural resources. 
 
The second study aimed at the preclinical detection of early markers for AD. Mutations on the 
PSEN1 gene are transmitted in an autosomal dominant manner and lead to familial 
Alzheimer’s disease (FAD). FAD is characterized by an earlier onset and a faster disease 
progression compared to sporadic AD.  
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We examined five nondemented members of a family with FAD. A young (20 years) and a 
middle-aged (45 years) person carried the C410Y mutation on the PSEN1 gene. Disease onset 
in families bearing this mutation is around 48 years. Both mutation carriers showed selective 
memory impairments in tasks of episodic memory. Moreover, the young mutation carrier 
exhibited enhanced brain activity in a memory-related network during episodic learning and 
retrieval, as compared to 21 healthy control subjects and to family members without the 
mutation. In contrast, the middle-aged mutation carriers showed decreased activity in a 
memory-related network during episodic learning and retrieval.  
The enhanced activity in the young mutation carrier might reflect compensatory mechanisms 
in response to accumulating, memory-affecting AD neuropathology. Conversely, reduced 
activity in the middle-aged mutation carrier might reflect substantial neural dysfunction in 
more advanced stages of AD-related neuropathological deposition.  
Our data suggest, that by applying functional neuroimaging and sensitive memory tasks, 
preclinical memory dysfunction can be detected three decades before clinical onset of AD. 
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Introduction 
 
Our memories of everyday life – of people, places and events – define who we are (Squire 
and Kandel, 1999). Life without memory is hardly imaginable, since our thoughts, goals and 
wishes are almost constantly dependent on memories of ourselfes, of our experiences and our 
environment. In a certain sense, our own personality is strongly connected to our memory. I 
would go even further and claim that our own personality is mediated to a large extent by our 
memories (although, it was not the aim of this doctoral thesis to prove that…). The most 
striking example for this notion comes from Alzheimer’s Disease (AD) patients. Everybody 
who works or lives with AD patients can approve what drastic consequences the process of 
memory loss during the course of the disease has on the personality and the character of such 
a person. The devastating effects that memory disorders can have on normal life, was one of 
the major points why I got interested in studying memory. During my psychology study at the 
University of Zurich neuroimaging became more and more a valid and established method for 
investigating basic functions of human cognitive capacities and their underlying neural 
correlates, thereby, to some extent, bridging the gap between structure and function. Research 
on the brain literally exploded during that time, and this period was accordingly named 
‘Decade of the brain’. For my part, I was fascinated, that one could observe the brain at work. 
The logical consequence was a diploma thesis on the cognitive function of my primary 
interest – memory – investigated with the method that fascinated me the most – functional 
magnetic resonance imaging (fMRI). During my diploma work I started to gain extensive 
knowledge about memory and its neural correlates and learned a lot about the power of 
neuroimaging – and its pitfalls. After my psychology masters degree, I was ready to go a step 
further and deepen my knowledge. When I started the PhD program in cognitive 
neuroscience, the first studies were published that investigated genetic influences on normal 
memory function using neuroimaging techniques. I was attracted by the interdisciplinary 
nature of this research and decided to work on two projects combining genetics, neuroimaging 
techniques and quantitative neuropsychological methods. 
 
There is an ongoing debate about the extent to which nature and nurture influence human 
cognition. About 20’000 genes are considered to play a role in the development, plasticity and 
maintenance of the central nervous system (CNS). 6 million single nucleotide polymorphisms 
(SNPs) are believed to be implicated in the genetic variability in worldwide populations, but it 
is likely that only a minority of the common variations is functional in nature, thus resulting in 
changes in the expression or the behavior of coded proteins. The variation in normal human 
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cognition is related to many factors. Twin studies suggest, that about 50% of the 
interindividual variability in memory ability is attributable to genetic factors (McClearn et al., 
1997), thus individual single gene effects are expected to be small. This doctoral thesis is part 
of an attempt to identify genes that influence memory capacity, memory-related brain 
function and structure in health and in AD. One study focused on the influence of naturally 
occurring genetic variations on normal interindividual mnemonic capacities in young persons. 
The other study sought to determine preclinical signs of AD in carriers of an autosomal 
dominantly transmitted causative gene associated with a familial form of AD.  
 
In the following theoretical part I will first give a short overview on the memory systems 
model, emphasizing on episodic and semantic memory and its neural correlates, because we 
mainly examined genetic influences on declarative memory. I will then introduce studies that 
reported polymorphisms in the brain derived neurotrophic factor (BDNF) gene, the serotonin 
(5-HT) 2a receptor encoding gene, and the prion protein (PRNP) gene which have been 
shown to influence normal human memory variability. Finally, I will review literature about 
the two genes that were examined in this doctoral thesis; the apolipoprotein E gene (APOE) 
and the presenilin 1 gene (PSEN1). 
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1. Genes and memory 
 
1.1. Episodic memory and its neural correlates 
 
Memory is divided into short-term and long term memory. In cognitive psychology short term 
memory is also termed ‘working memory’ and referred to as a limited capacity system 
allowing the temporary storage (up to one minute) and the manipulation of information 
necessary for such complex tasks as comprehension, learning and reasoning (Baddeley and 
Hitch, 1974). Long-term memory contents, on the other hand, are thought to be consolidated 
through protein synthesis at the synapse, leading to a definitive and permanent storage of 
information over time, hence enabling the recall of recent and remote events. The parcellation 
of long-term memory into distinct subsystems has a long history but became a topic of 
experimental inquiry only after the middle of the 20th century. In 1957 Scoville and Milner 
reported the case H.M., probably the most famous patient in memory research. H.M suffered 
from medication-resistent epileptic seizures. After the bilateral resection of the medial 
temporal lobes (MTL) the seizures vanished, but, as a consequence, the patient lost its ability 
to acquire new memories (anterograde amnesia) and the ability to consciously retrieve 
memories formed before the surgical intervention (retrograde amnesia). Nevertheless, short-
term memory, intelligence, motor, perceptual, language and attentional abilities were 
preserved. This was the first report that made clear, that MTL structures, especially the 
hippocampus at its core, are of crucial importance for long-term memory (see Fig. 1 one for 
an illustration of MTL structures, including the hippocampus proper with fields CA1-CA4, 
dentate gyrus and subiculum, the rhinal cortices and the parahippocampal gyrus).  
 
 
Fig. 1. Coronal view of the anatomical subdivisions of the MTL depicted on a structural T1-MRI scan of the 
author’s brain. 
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Cohen and Squire (1980) observed an impaired ability to learn and remember declarative or 
data-based information in amnesic patients, while learning and remembering of procedural or 
rule-based information was preserved. This differentiation between the impairment for 
declarative memory (knowing what) and the preservation of non-declarative memory 
(knowing how) was the basis for a model of long-term memory systems, as proposed by 
Squire and Zola (1996). In this model, long-term memory is divided into declarative and non-
declarative memory (Fig. 2).  
 
 
Fig. 2. A taxonomy of mammalian long-term memory systems. Listed are brain structures thought to be 
especially important for each form of declarative and nondeclarative memory (Squire and Zola, 1996).  
 
 
Declarative memory is defined as the acquisition, retention, and retrieval of knowledge that 
can be consciously and intentionally recollected (Cohen and Squire, 1980). Declarative 
memory was further subdived by Tulving (1972) into memory for events (episodic memory) 
or facts (semantic memory). Tulving characterized episodic memory as the capacity to 
recollect where and when past events occurred. Because of their spatio-temporal connotation 
episodic memories are often referred to as autobiographical memories. Tulving and 
colleagues have recently refined their definition of episodic memory as the emphasizing 
qualities of the subjective consciousness and a sense of time in retrieving past experiences 
(Tulving, 2002; Tulving and Markowitsch, 1998). An example: If you think about yesterday 
evening, when you were riding with your bike along the river, you might consciously and 
vividly re-experience that episode. You might recall the time you were riding your bike, what 
the color of the river looked like or even what you were thinking during your little trip out in 
the nature. All these memory contents are of an episodic character because of their spatio-
temporal context. Semantic memory contents, however, are not attributable to any specific 
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time or place. Typical contents of semantic memory would be general factual knowledge of 
the world, in our example this would be knowledge about bicycles, such as bikes have two 
wheels, two pedals, a bell to ring, etc. 
Experimentally, declarative memory is accessed through explicit learning tasks, where 
participants are presented with stimuli that have to be retrieved after a determined delay.  
There are three different forms of retrieval tests: a) free recall, where participants have to 
freely retrieve learned stimuli without any help or hint; b) cued recall, where participants are 
given a cue which elicits the retrieval of the stimulus, for example the first letter or syllable of 
previously presented words; c) recognition, where stimuli are presented along with one or 
more new distracter items and where participants then have to indicate the previously learned 
stimuli. 
As mentioned above, studies with amnesic patients (Kartsounis et al., 1995; Rempel-
Clower et al., 1996; Zola-Morgan et al., 1986) indicated that episodic declarative memory 
depends on the integrity of MTL and diencephalic structures, which interact with the 
neocortex. The hippocampal system is anatomically inter-connected with polymodal 
neocortical association areas; afferent input from the neocortex converges into the entorhinal 
and perirhinal cortex, is then projected to the hippocampal subdivisions and finally 
backpropagated to the neocortex through the parahippocampal gyrus (Amaral et al., 1987; 
Cohen and Eichenbaum, 1993; Insausti et al., 1987a; Insausti et al., 1987b; Squire and Zola, 
1996; Van Hoesen and Pandya, 1975; Van Hoesen et al., 1975; Van Hoesen and Pandya, 
1975). This anatomical feature allows the hippocampal system to interact with neocortical 
sites,  providing the ability for the relational binding of information coming from different 
cortical sites (Cohen and Eichenbaum, 1993). Cortical areas that have been activated at the 
time of encoding can be reactivated by the hippocampal system, thereby accomplishing the 
retrieval of a whole memory. 
Studies using quantitative methods to characterize memory loss in patients with more 
circumscribed lesions found that hippocampal damage, in particular, is typically associated 
with temporally-graded retrograde amnesia (Beatty et al., 1987; Rempel-Clower et al., 1996; 
Salmon et al., 1988; Squire et al., 1975). According to this evidence, the ‘consolidation 
hypothesis’, posits a time-limited role of the hippocampus in the storage and retrieval of new 
information, while permanent storage depends on a broadly distributed cortical network. The 
neural network model of consolidation suggests that MTL structures bind together multiple 
neocortical sites where memory representations are stored and that after repeated re-activation 
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the cortico-cortical connections become strong enough to support memory retrieval without 
the MTL (McClelland et al., 1995; Squire and Alvarez, 1995). 
With the advent of neuroimaging techniques, the precise role of the hippocampal 
formation and surrounding MTL structures has further been refined. Activity in the 
hippocampal region has been correlated with the associative, recollective, and contextual 
aspects of declarative episodic memory (Cabeza and Nyberg, 2000; Cohen and Eichenbaum, 
1993; Davachi et al., 2003; Henke et al., 1997; Henke et al., 1999b; Lepage et al., 2000; 
Mayes et al., 1998; Montaldi et al., 1998; Schacter and Buckner, 1998; Small et al., 2001; 
Sperling et al., 2001). However, the findings do not reveal a sharp distinction between the 
hippocampal region and the adjacent MTL structures. Recent findings implicated both the 
hippocampal region and the parahippocampal cortex in recollective memory and in the 
encoding and retrieval of associations (Davachi et al., 2003; Duzel et al., 2003; Eldridge et al., 
2000; Henke et al., 1997; Henke et al., 1999b; Kirwan and Stark, 2004; Ranganath et al., 
2004; Small et al., 2001; Sperling et al., 2001; Sperling et al., 2003; Stark and Squire, 2001; 
Yonelinas et al., 2001). 
 
The neural topology of semantic declarative memory is less clear. Studies in patients suffering 
from semantic dementia have identified neocortical areas of the temporal lobe, such as the left 
inferior frontal gyrus and the lateral temporal gyri as the underlying neural substrates (Cabeza 
and Nyberg, 2000; Kopelman, 2002; Martin and Chao, 2001; Pilgrim et al., 2002; Wagner et 
al., 2001). Patients with semantic dementia are struck by focal atrophy in the temporal 
neocortex, while the MTL is relatively spared. As a consequence, they are strongly impaired 
in the retrieval of general facts of the world but show almost normal performance in tasks of 
episodic memory. It is still a matter of debate, whether the hippocampus is involved in the 
retrieval and the acquisition of semantic memory (Squire and Zola, 1998), the acquisition only 
(Cipolotti et al., 2001) or none of both (Vargha-Khadem et al., 1997). 
 
In contrast to declarative memory, nondeclarative memory is divided into heterogeneous 
subforms, such as procedural memory (skills and habits), priming and perceptual learning, 
simple classical conditioning and nonassociative learning. These kinds of memory are not 
dependent on conscious awareness for the learning episode or the learning material and are 
mostly preserved in amnesic patients with MTL structure damage. Nondeclarative memory is 
subserved by different extra-MTL structures such as the neocortex, cerebellum, striatum, 
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amygdala and reflex pathways (for reviews please see (Gabrieli, 1998; Squire, 1992; Squire et 
al., 1993).  
 
 
1.2. The brain-derived neurotrophic factor (BDNF) gene, the serotonin (5-HT) 2a  
  receptor encoding gene and the prion protein gene (PRNP) 
 
As yet, three genetic polymorphisms have been identified that play a role in the normal 
variabilty of human memory capacity. De Quervain and colleagues (2003) investigated the 
effects of a frequent polymorphism (H452Y) of the gene encoding the serotonin (5-
hydroxytryptamine or 5-HT) 2a receptor on human memory. This polymorphism predicts an 
amminoacid substitution (His to Tyr) at residue 452. Serotonin has been implicated in 
learning and memory. Its receptor subtypes, including the 5-HT2a receptor, are localized on 
‘cognitive’ pathways, with the hippocampus and frontal cortex as the main target structures 
(Buhot, 1997). The authors examined 349 subjects, split into two independent populations of 
either university students (academics) or age-matched employees/trainees without an 
university degree (non-academics). Subjects engaged in a word learning/retrieval task that 
was conducted on two consecutive days. On the first day, subjects learned six sets of 
semantically unrelated nouns (five nouns per set), presented at a rate of one word per second, 
for immediate recall. An unexpected delayed free recall of the learned words was conducted 
after 5 minutes and after 24 hours. In both, the academic and the non-academic group, 
His/Tyr subjects showed 21% poorer memory performance in the 5 minutes delayed free 
recall. Furthermore, after splitting the whole sample into good and poor learners, a higher 
proportion of His/Tyr subjects were found in the poor learners group. These results suggest 
that the (H452Y) polymorphism of the 5-HT2a receptor encoding gene negatively affects 
protein-synthesis independent memory recall after 5 minutes but not after 24 hours or during 
immediate recall. However, although the study identified one of the presumably many genes 
involved in normal human memory capacity, it was not able, because of its associative nature, 
to uncover neural mechanisms underlying the poorer performance of polymorphism carriers.  
 
Papassotiropoulos et al. (2005) investigated the effects of the common Val129Met 
polymorphism of the prion protein gene (PRNP) on long-term memory in 354 healthy young 
humans. Long-term memory depends on protein synthesis and on molecular long-term 
changes at the neuronal synapse (Kandel, 2001). It has been shown in yeast and Aplysia1 that 
                                                      
1 Aplysia: a marine snail in which substantial research on the molecular basis of short and long-term memory has been 
conducted, primarily by Nobel Prize winner Eric R. Kandel and co-workers. 
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a prion-like protein switch might help to maintain long-term synaptic changes (Si et al., 
2003a, 2003b), suggesting that genes encoding prion-like properties could be associated with 
human long-term memory. The prion protein Prp is encoded by the polymorphic PRNP gene 
in humans. The common methionine/valine polymorphism at codon 129 (M129V) modulates 
the folding behaviour of the protein and controls susceptibility to prion diseases (Petchanikow 
et al., 2001; Tahiri-Alaoui et al., 2004; Palmer et al., 1991). Papassotiropoulos et al. (2005) 
found that the three investigated single nucleotide polymorphisms2 (SNPs) (i.e. the 129MM, 
the 129MV, and the 129VV genotype) in the genomic region of PRNP were significantly 
associated with long-term memory but not with short-term memory. Moreover, after 
excluding confounding factors such as adjacent genomic loci, population structure and 
sampling bias the authors found that subjects homozygous or heterozygous for the 129M 
variant exhibited 17% better memory performance in the 24 hours recall of previously learned 
words. These results suggest that the human prion protein in genetically associated with long-
term memory. However, like de Quervain et al. (2005), this study could not deliver substantial 
information on the neural mechanisms underlying better memory in the met allele carriers. 
 
A third gene to play a role in human memory is the brain derived neurotrophic factor (BDNF) 
encoding gene. BDNF is expressed in the brain, most strongly in the hippocampus (Murer et 
al., 2001). It has been implicated in both early phase long-term potentiation (E-LTP) (Bliss 
and Collingridge, 1993), which involves rapid increases in intracellular calcium 
concentrations and subsequent activation of protein kinases, and late phase long-term 
potentation (L-LTP) (Kandel, 2001), which is characterized by the recruiting of the cAMP 
and CREB signalling pathways to direct protein synthesis-dependent changes in structure and 
function (Lu and Gottschalk, 2000; Poo, 2001). Moreover BDNF is involved in the regulation 
of cell survival, proliferation, and synaptic growth in the developing central nervous system 
(CNS). Val66met is the only reported common polymorphism that has been identified in the 
BDNF gene. It is a SNP at nucleotide 196 (G/A) producing an aminoacid substitution (valine 
to methionine) at codon 66. Egan and colleagues (2003) found that rat hippocampal neurons 
transfected with the met allele3 exhibit abnormal intracellular trafficking and regulated 
secretion of BDNF in comparison to those transfected with the val allele. The same study 
                                                      
2 SNP (single nucleotide polymorphism): a variant in a single nucleotide at a specific location in the genomic 
sequence that may or may not have functional consequences for the protein, depending on the type of 
substitution and the context. A non-functional SNP (i.e. the SNP is silent or in a non-coding area of the gene) 
may still be in a monitoring relation with a functional mutation (e.g. if it is physically close on the genomic 
sequence). 
3 Allele: a variant of a gene 
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further established an association of the met allele with deficits in episodic memory in healthy 
human subjects and showed that the met allele is linked with diminished levels of 
hippocampal N-acetyl aspartate, a putative marker of neuronal integrity and synaptic 
abundance. To tackle the contribution of the  BDNF val66met polymorphism on human 
memory and memory-related hippocampal activity, Hariri and colleagues (2003) studied 28 
healthy volunteers with fMRI while they encoded and subsequently retrieved complex, novel 
scenes. This simple declarative memory task is known to be dependent on the hippocampal 
formation (Gabrieli, 1998). 14 subjects carried the Val/Val genotype4, the variant associated 
with normal intracellular trafficking of BDNF and better episodic memory, while 12 subjects 
carried the val/met and two the met/met genotype. Importantly, the genotype groups were 
matched for gender, age, mean intelligence quotient and the apolipoprotein E ε4 allele. The 
apolipoprotein E ε4 allele5 has been associated with a higher risk for the development of late 
onset sporadic Alzheimer’s Disease (Corder et al., 1993) and was found to have an impact on 
memory-related brain activity in healthy elderly subjects (Bondi et al., 2005; Bookheimer et 
al., 2000). The comparison of both groups revealed greater memory-related hippocampal 
activity during encoding and retrieval in subjects homozygous for the BDNF Val allele. 
However, BDNF genotype did not alter activity within a distributed network (e.g. 
inferotemporal, parietal and frontal areas) subserving general visuospatial information 
processing, hence strengthening the specificity of this BDNF effect on hippocampal activity. 
In the memory tasks, Val homozygotes were more accurate at recognizing both ‘new’ and 
‘old’ scenes during retrieval, although encoding accuracy was comparable between groups. 
Moreover, using a modified hierarchical stepwise regression analysis, the authors showed that 
~25% percent of the total variation in recognition memory was explained by an interaction 
term between the BDNF val66met genotype and the mean left hippocampal activity during 
encoding.  
A recent study of the same group (Pezawas et al., 2004) showed that the val66met variation in 
the BDNF gene not only impacts on memory performance and memory-related hippocampal 
acitivty, but also on hippocampal and prefrontal cortex morphology, brain areas related to 
learning and memory. The authors analyzed high-resolution magnetic resonance images of 
111 normal healthy volunteers with optimized voxel-based morphometry (VBM), an 
automated morphological imaging technique (Ashburner and Friston, 2000). Bilateral 
                                                      
4 Genotype: allelic combination at a locus (expressed as homozygote aa, homozygote AA, or heterozygote Aa) 
5 Please refer to chapter 1.3. of this doctoral thesis for a comprehensive overview of the apolipoprotein E gene 
and its implication in Alzheimer’s Disease, declarative memory, memory-related neural activity, and brain 
morphology. 
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reductions of hippocampal gray matter volumes and volume reductions in the dorsolateral 
prefrontal cortex were found in met carriers compared with Val homozygous carriers. 
According to the authors, these data suggest, that reduced memory functions of met carriers 
might, at least in part, be explained through changes of synaptic and cellular plasticity and not 
exclusively by an effect of rapid changes of neural transmission during memorization. They 
add, that the mechanism of this structural effect presumably relates to abnormal regulated 
secretion of met-BDNF alleles, which alters activity-dependent processes of cortical 
development and plasticity. 
 
In this section I reviewed studies that identified genes that are involved in normal human 
memory variability. So far, three polymorphisms have been detected to play a key role; the 
val66met polymorphism in the BDNF gene, the H452Y polymorphism in the 5-HT2a receptor 
encoding gene, and the Met129Val polymorphism in the prion gene. While the H452Y 
polymorphism of the 5-HT2a receptor encoding gene was associated with poorer memory 
performance in young and healthy subjects, the common Met129Val polymorphism in the 
PRNP gene was related to better long-term memory performance. Last but not least, the 
val66met polymorphism in the BDNF gene was confirmed to have an impact on hippocampal 
cognition, neurophysiology, neurochemistry and morphology. In the following two sections, I 
will review literature about the genes of interest in this doctoral thesis; the APOE gene and 
the PSEN1 gene. The implication of both the APOE gene and the PSEN1 gene on normal 
human memory variability are still unknown, therefore a focus will be laid on studies that 
examined effects of these genes on memory in light of a preclinical detection of markers for 
AD. 
 
 
1.3. The apolipoprotein E (APOE) gene 
 
Apolipoprotein E (apoE) has emerged as an important molecule in several biological 
processes. This plasma glycoprotein is involved in cholesterol metabolism, immunoregulation 
and cognition (Mahley and Rall, Jr., 2000). A primary metabolic role for apoE is to transport 
and deliver lipids from one tissue or cell type to another (Mahley, 1988; Mahley and Huang, 
1999; Mahley and Ji, 1999). The three major isoforms, apoE4, apoE3, and apoE2 can be 
distinguished from one another only by single amino acid substitutions. These changes have 
profound functional consequences at both the cellular and molecular levels. Isoform specific 
effects on the normal variation of plasma lipids have been described in population studies. 
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These studies have reported, that apoE3 contributes little to variation, whereas apoE2 and 
apoE4 have definite impacts on lipid and lipoprotein levels (Utermann, 1985). 
ApoE is a polymorphic protein arising from three alleles at a single locus. In humans the 
Apolipoprotein E gene is located on chromosome 19. It is synthesized and secreted primarily 
by the liver, brain, skin, and tissue macrophages throughout the body (Mahley, 1988). It 
possesses two tightly linked coding sequence polymorphisms, which give rise to three allelic 
variants (ε2, ε3, ε4). Thus, six phenotypes are possible and have already been detected in 
human subjects: three homozygous phenotypes (ε2/ε2, ε3/ε3, ε4/ε4) and three heterozygous 
phenotypes (ε2/ε3, ε2/ε4, ε3/ε4). Population studies yielded valuable information about 
APOE allele frequencies: the most common variant, ε3, is present in approximately 75% in 
Caucasians, while ε4 and ε2 are present in only 15% and 10%, respectively (St George-
Hyslop, 2000). As a result, the frequencies of the six APOE phenotypes are approximately: 
55% ε3/ε3, 25% ε3/ε4, 15% ε2/ε3, with the other phenotypes ε2/ε2, ε4/ε4, ε2/ε4 making up 
the remaining 1-2 % (Mahley and Rall, Jr., 2000). 
 
The APOE ε4 allele (APOE4) has an extensive record of deleterious effects on several 
biological processes. It has been associated with increased heart disease risk (Davignon et al., 
1988; Menzel et al., 1983; Utermann et al., 1984) and coronary artery disease (Davignon et 
al., 1987; Wilson et al., 1994). The most prominent role of APOE4, however, is it’s 
association with an increased risk for developing sporadic late onset Alzheimer’s disease 
(Corder et al., 1993; Polvikoski et al., 1995; Roses et al., 1994; Saunders et al., 1993; 
Strittmatter et al., 1993a). Carriers of at least one ε4 allele have a threefold increased risk for 
the development of AD (Saunders et al., 1993) with a younger age at the onset of dementia 
(Corder et al., 1993; Roses et al., 1994). APOE4 is further associated with the hallmarks of 
AD - amyloid plaque deposition and neurofibrillary tangle formation (Bennett et al., 2003; 
Tiraboschi et al., 2004), with a faster rate of ß-amyloid protein deposition (Roses, 1995; 
Schmechel et al., 1993), and with decreased longevity (Cauley et al., 1993; Davignon et al., 
1987; Schachter et al., 1994). In contrast, the possession of an ε2 allele appears to confer a 
protective effect against AD (Corder et al., 1994). It has been further associated with an older 
age at the onset of dementia (Roses et al., 1994), with a reduced decline in episodic memory 
in older persons (Wilson et al., 2002), slower rates of ß-amyloid protein and neurofibrillary 
tangle deposition (Polvikoski et al., 1995; Schmechel et al., 1993), a decreased risk of 
atherosclerosis (Davignon et al., 1988; Wilson et al., 1994), and increased longevity (Cauley 
et al., 1993; Davignon et al., 1987; Schachter et al., 1994). 
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Detrimental effects of APOE4 on memory (Albert et al., 2001; Backman et al., 2001; Baxter 
et al., 2003; Bondi et al., 1995; Bondi et al., 1999; Chen et al., 2001; Fuld et al., 1990; Grober 
and Kawas, 1997; Hyman et al., 1996), executive functions (Rosen et al., 2005), and visual 
attention (Greenwood et al., 2000) have been found in several studies with nondemented 
middle-aged and elderly subjects. Often the decline in episodic memory is evident some years 
prior to the development of dementia and has been shown to predict the subsequent 
development of AD. For example Bondi et al. (1999) found poorer mean performances on 
delayed recall in 43 nondemented older APOE4 carriers when compared 
neuropsychologically to participants without a copy of the ε4 allele. At baseline the groups 
did not differ on age, gender, education, or global cognitive status. Significantly more APOE4 
participants developed probable or questionable AD, compared with non-APOE4 participants, 
suggesting that group differences resulted from a preponderance of preclinical AD cases 
within the ε4 group and not from a direct influence of APOE genotype on cognition. In a 
recent longitudinal study Caselli and colleagues (2004) tested 45 APOE ε4/ε4 carriers, 42 
APOE ε3/ε4 carriers and 93 APOE ε4 noncarriers with a mean age of 60 years. APOE ε4 
carriers among 50 to 59 years exhibited poorer memory performance, as compared to ε4 
noncarriers, in multiple measures of verbal memory over a mean period of 33 months. No 
differences were found in the domains of language, spatial skills, or executive functions.  
Detrimental effects of APOE4 are, however, not restricted to episodic memory, but do 
encompass other cognitive functions as well. Rosen et al. (2005) tested twenty ε4 carriers and 
twenty ε4 noncarriers on a category fluency task. Subjects were tape recorded while saying 
animal names for ten minutes. The ε4 carriers generated significantly fewer names and 
clusters of animals, and took significantly longer to access clusters when compared to the ε4 
noncarriers. The authors attributed the APOE4 carriers’ deficits in executive functions to a 
reduced attentional capacity. Indeed Greenwood et al. (2000) showed that specific 
components of visual attention are affected by the APOE genotype. They found that middle-
aged nondemented APOE4 carriers exhibited deficits when visual attention was spatially 
directed by cues in tasks of visual discrimination and visual search, in comparison to APOE4 
noncarriers. Consistent with the aforementioned findings linking APOE and cognition are 
results from a study which showed that the absence of APOE4 is associated with higher levels 
of cognitive functioning in very old (75-98 years) adults (Riley et al., 2000). 
 
The association of APOE4 with the hallmarks of AD - amyloid plaque deposition and 
neurofibrillary tangle formation (Bennett et al., 2003; Tiraboschi et al., 2004) – suggests that 
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APOE4-related cognitive deterioration is mediated by these neuropathological events. 
Support for this notion comes from studies with structural and functional neuroimaging. 
Amyloid deposition and neurofibrillary tangle formation lead to neuronal loss and synaptic 
degradation that is manifested as brain morphological loss in AD, starting in MTL structures 
and spreading throughout the neocortex in later stages of the disease (Braak and Braak, 1996; 
Delacourte et al., 1999). Hippocampal volume loss is consistently found in clinically 
diagnosed AD patients (Convit et al., 1997; Kesslak et al., 1991; Killiany et al., 1993). 
Hippocampal atrophy in older persons with mild cognitive impairment (MCI) is associated 
with subsequent development of clinical AD (de Leon et al., 1993; Killiany et al., 2000). 
Similar but less pronounced changes in hippocampal morphology occur in healthy adults with 
APOE4. A study with ten pairs of cognitively normal twins (mean age = 62.5 years) found 
that individuals carrying an APOE ε4 allele had smaller hippocampi than those lacking an ε4 
allele, despite comparable performance levels on standardized neuropsychological tests 
(Plassman et al., 1997). Reiman et al. (1998) compared hippocampal volumes of 11 
cognitively normal homozygous APOE4 carriers (50 to 62 years of age) to 22 persons without 
APOE4. The APOE4 homozygotes showed nonsignificant trends for smaller left and right 
hippocampal volumes. Overall, small hippocampal volumes were associated with reduced 
performance on a long-term memory test. A recent study (Lemaitre et al., 2005) using both 
voxel-based morphometry and region of interest analysis for hippcampal volume estimation 
studied a cohort of 750 healthy elderly volunteers (age range 63-75 years). Significant 
decrease of grey matter in ε4 homozygous subjects (n=12), as compared both to ε4 
heterozygous subjects (n = 175) and to noncarriers (n = 563) was found bilaterally in the 
MTL, including the hippocampus and extending over the superior temporal gyrus. However, 
no significant difference was observed between ε4 heterozygous subjects and noncarriers at 
the level of the MTL. Follow up of the cohort cognitive performances over 4 years revealed 
an increased relative risk of the homozygous ε4 carriers for cognitive impairment. These 
results do not argue against a gene-dose dependent effect of APOE on brain morphology since 
a present ε4 effect on hippocampal volumes was indeed present in heterozygotes, but was 
small enough to have been overwhelmed by the much greater effect of intersubject anatomical 
variability that increases with age (Jack, Jr. et al., 1998). 
 
Positron emission tomography (PET) studies of clinically diagnosed AD patients have shown 
reduced cerebral metabolism and blood flow in temporal and parietal cortices (Alexander et 
al., 1997; Haxby et al., 1985; Ibanez et al., 1998; Rossor et al., 1996). Similar metabolic 
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changes measured with PET have been reported in APOE4 carriers (de Leon et al., 2001; 
Reiman et al., 2002a; Reiman et al., 2002b; Reiman et al., 2004; Reiman et al., 2005; Reiman 
et al., 1996; Scarmeas et al., 2004; Small et al., 2000; Small et al., 1995). Small et al. (1995) 
examined middle-aged persons with MCI and with a positive family history of AD. APOE4 
carriers showed a lower overall level of parietal metabolism and greater hemispheric 
asymmetry. These findings were confirmed in a follow-up study with another sample of 
participants with MCI (Small et al., 2000). Here, a single copy of the APOE ε4 allele was 
associated with lowered inferior parietal, lateral temporal, and posterior cingulated 
metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. A 
study with cognitively normal individuals found that APOE4 homozygotes showed reduced 
rates of glucose metabolism in parietal, temporal, prefrontal, and posterior cingulated regions 
(Reiman et al., 1996). A recent study of the same group examined 160 cognitively normal 
subjects 47-68 years of age with PET. The sample included 36 APOE4 homozygotes, 46 
heterozygotes, and 78 APOE4 noncarriers who were individually matched for their age, 
gender, and educational level. The authors found that ε4 gene dose was correlated with lower 
cerebral metabolic rate for glucose in regions of the precuneus, the posterior cingulated, 
parietotemporal, and frontal cortex.  
Two studies using functional imaging have reported altered patterns of brain activation 
in APOE4 carriers (Bondi et al., 2005; Bookheimer et al., 2000). Bookheimer et al. (2000) 
studied 30 subjects (aged 47 to 82 years) who were cognitively healthy, and of whom 16 were 
APOE4 carriers and 14 were homozygous APOE3 carriers. Mean age and level of education 
were matched between both groups. The blood oxygenation level dependent (BOLD) fMRI-
signal was measured, while subjects memorized and recalled unrelated pairs of words and 
during a resting baseline condition. Interestingly, both the magnitude and the extent of brain 
activation during memory-activation tasks in regions affected by AD, including the left 
hippocampal, parietal, and prefrontal regions were greater among the carriers of the ε4 allele 
than among carriers of APOE3. During recall of the learned material, APOE4 carriers showed 
a greater average increase in signal intensity in the hippocampal region and greater mean 
number of activated regions throughout the brain. After two years 8 ε4 carriers and 6 ε3 
carriers were reassessed. Significant activation in the left hemisphere at baseline was 
significantly correlated with the degree of longitudinal verbal memory decline. The authors 
argue that the increased level and volume of activation in the APOE4 group may effectively 
serve a compensatory role, wherein subjects use additional cognitive resources to bring 
memory-related performance to a normal level. Indeed, increased activation in prefrontal 
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cortex is also seen in AD patients and could be indicative of a compensatory response (Grady 
et al., 1993; Grady and Parasuraman, 1995). The same line of argumentation is followed by a 
recent study. Using fMRI, Bondi et al. (2005) examined twenty nondemented participants 
with normal episodic memory function during a picture-encoding task. Nondemented older 
adults with APOE4 (n = 10) showed greater magnitude and extent of BOLD brain response in 
multiple regions (e.g. precuneus, frontal, temporal, and cingulated gyri) during learning of 
new pictures relative to the matched APOE3 carriers. Again, the increased activity in APOE4 
carriers was explained with the ‘Compensatory Hypothesis’. The authors hypothesize that 
after an initial decline in memory proficiency following damage to MTL structures, patients 
in the preclinical stage of AD are able to effectively recruit compensatory brain resources 
(e.g. frontal and temporal cortical regions important for executive functions and semantic 
memory) to halt or slow further memory decline for a period of time. 
 
These neuroimaging studies have yielded generally consistent results. However, all studies 
were performed in middle-aged to elderly subjecs (50-65 years), which on one hand increases 
confidence that the findings are not confounded with age-related changes. On the other hand, 
these studies might only have mapped APOE4 effects through the progressing 
neuropathological changes in preclinical AD cases. Valuable insights into a distinct APOE 
genotype mediated effect on normal neurophsyiologic functioning of memory can only be 
achieved in healthy normal subjects that are, with great probability, devoid of any such 
neuropathological changes.  
Interestingly, detrimental effects of APOE4 are almost only observed in middle-aged 
to older human subjects and in aged animals. APOE4  has been also experimentally related to 
impaired hippocampal plasticity (Levi et al., 2003) and lower density of dendritic spines (Ji et 
al., 2003) in aged transgenic mice.  
Advantageous effects of APOE4 on the other hand, have almost exclusively been 
reported in utero, in childhood, or in young adulthood. Zetterberg et al. (2002) investigated 
the role of APOE polymorphisms in embryonic development and analyzed the APOE 
genotypes of 81 spontaneously aborted embryos and 110 adult controls. The ε4 allele was 
significantly less frequent in the spontaneous abortion group than in the control group, while 
the frequency of ε3 was significantly increased, suggesting that APOE4 might have protective 
effects during embryogenesis. Ravaja et al. (1997) measured heart rate (HR), finger blood 
volume, and skin conductance level during experimentally induced stress in 28 healthy 16-
year-old boys. They found that APOE4 noncarriers showed significantly greater HR reactivity 
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and significantly greater task levels of HR and HR variability during mental stress, suggesting 
that APOE4 is associated with less cardiovascular responsivity to mental stress in adolescent 
boys. Beneficial effects of APOE4 were also found in human cognitive functions. Hubacek et 
al. (2001) found an association of APOE4 with higher education. In the group with higher 
education 24.4% had the ε4 allele, while only 7.3% carried the ε2 allele. An inverse 
relationship was found in subjects that left school at age 15 – 8.3% had the ε4 allele and 
13.9% had the ε2 allele. Also, eighty-seven percent of the subjects with APOE4 reached 
higher education, while this was the case only for 54.5% of APOE2 carriers. This indicates a 
possibility for a role of APOE polymorphisms in intelligence and the ability to learn. As a 
matter of fact, Yu et al. (2000) found modest performance intelligence quotient increases in 
young ε4 allele carrier females. 
 
While the detrimental effects of APOE4 seem to be tightly coupled to the neuropathology of 
AD (Kounnas et al., 1995; LaDu et al., 1997; LaDu et al., 1994; Ma et al., 1994; Miyata and 
Smith, 1996; Sanan et al., 1994; Strittmatter et al., 1993b; Wisniewski et al., 1994; Yankner et 
al., 1990), the beneficial effects might be best explained through an evolutionary line of 
argumentation (Finch and Sapolsky, 1999; Mahley and Rall, Jr., 2000). It has been suggested 
that, even though ε3 is the most common allele in humans, ε4 may be the ancestral allele 
(Hanlon and Rubinsztein, 1995; Mahley, 1988). One might expect, that both ε2 and ε4 should 
confer some selective advantages that have allowed them to persist in the human population. 
In support for the view that ε4 might be the ancestral allele is the fact, that most animals have 
E4-like apoE, and especially significant is that all great apes, the closest living ancestors of 
humans, have the ε4-like allele and do not display multiple isotypes (Hanlon and Rubinsztein, 
1995). A lot of evidence so far suggests that ε4 is a deleterious allele. However, the question 
remains why it persisted at such a high frequency. One possible answer is delivered by Finch 
and Sapolsky (1999). They hypothesized that ε4 could have survived because of its 
advantageous effects early in life, when reproductive fitness is at its peak, but having a 
disadvantageous role later in life.  
 
 
1.4. The presenilin 1 (PSEN1) gene 
 
The presenilins are evolutionary conserved transmembrane proteins that regulate cleavage of 
certain other proteins in their transmembrane domains. The proteins encoded by the presenilin 
genes are 467 (PS1) and 448 (PS2) amino-acids long, and there is strong sequence homology 
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between the two (Czech et al., 2000). Presenilin homologues are found also in animals and 
plants, and a functional conservation of presenilins has been shown between humans and 
distantly related species (e.g. the nematode C. elegans) (Baumeister et al., 1997). The 
physiological functions of presenilins have been studied extensively in transgenic mouse 
models. PS1 has a specific role in neural development by acting on the notch6 signalling 
pathway. Lack of PS1 results in an embryonic lethal phenotype, which is reminiscent to the 
phenotype caused by a notch knock out (Shen et al., 1997; Wong et al., 1997). Similar to the 
notch knock out, lack of PS1 expression results in abnormal pattering of the axial skeleton 
and spinal ganglia. Besides this, presenilins were also implicated in synaptic plasticity, 
learning and memory, and neuronal survival. A recent study (Saura et al., 2004) examined 
conditional double knock out mice lacking both presenilins in the postnatal forebrain and 
found impairments in hippocampal memory and synaptic plasticity. These deficits were 
associated with specific reductions in NMDA7 receptors and αCaMKII8. In contrast, a higher 
degree of LTP induction mediated by the expression of variants in the presenilin 1 gene 
(PSEN1) has been shown by other groups in mice expressing additional PSEN1 mutations 
(Barrow et al., 2000; Pybus et al., 2003). Thus, PS1 may specifically regulate cellular 
components necessary for LTP induction, and mutations in PSEN1 disrupt the normal cascade 
of events, leading to alterations in intercellular communication. 
The most prominent role of the presenilins, however, is their implication in AD 
pathogenesis. Early onset familial Alzheimer’s Disease (FAD) is transmitted in an autosomal 
dominant manner and accounts for ~10% of all AD cases (St George-Hyslop, 2000). 
Mutations in three genes have been linked to FAD: The amyloid precursor protein gene (APP) 
on chromosome 21 (Goate et al., 1991), the presenilin 1 gene (PSEN1) on chromosome 14 
(Alzheimer's Disease Collaborative Group, 1995; Sherrington et al., 1995) and the presenilin 
2 gene (PSEN2) on chromosome 1 (Levy-Lahad et al., 1995; Rogaev et al., 1995). PSEN1 is 
expressed throughout the brain, interestingly at high levels in cerebral regions that are 
affected in AD (i.e. hippocampus, cerebral cortex and amygdala) and in peripheral tissues. 
PSEN2 is expressed only at low levels in the brain, except in the corpus callosum, but highly 
expressed in some peripheral tissues (Rogaev et al., 1997). Low PSEN2 levels in the brain are 
compensated by a higher activity of PSEN1. This might explain, why PSEN2 muations are 
infrequent and incompletely penetrant compared with the fully penetrant PSEN1 mutations 
(Bird et al., 1996; Sherrington et al., 1996).  
                                                      
6 Notch is expressed in neural cells and is involved in the determination of neuronal fate during development. 
7 N-Methyl-D-Aspartate receptors are ionotropic glutamate receptors that are involved in long-term potentiation. 
8 Calmodulin dependent kinase II  
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As yet, more than 100 missense9 mutations of the PSEN1 gene are known with varying ages 
of onset of AD ranging from 25 years to 64 years (Rogaeva, 2002; Tandon et al., 2000). These 
pathogenic mutations modify amyloid precursor protein (APP) processing thereby leading to 
an enhanced Aß42 secretion (Scheuner et al., 1996). AD patients carrying PSEN1 or PSEN2 
mutations have significant increases of plasma Aß42 levels together with massive deposition 
of Aß42 in the brain (Iwatsubo, 1998; Lemere et al., 1996). The deposition of Aß42 is one of 
the earliest visible neuropathological features in AD. In FAD patients with PSEN1 muations, 
the deposition of Aß42 precedes overt neuronal loss (Lippa et al., 1998) or the appearance of 
neurofibrillary tangle formation, the other neuropathological hallmark of the disease (Braak 
and Braak, 1996).  
 
A variety of studies investigated pedigrees with different mutations on the PSEN1 gene and 
described the clinicopathological features of FAD (Alzheimer's Disease Collaborative Group, 
1995; Fox et al., 1997; Haltia et al., 1994; Heckmann et al., 2004; Janssen et al., 2000; 
Jimenez-Escrig et al., 2004; Rosselli et al., 2000). Neuropathologic changes in FAD are 
similar to changes in sporadic cases of AD, however, familial cases show initial clinical 
symptoms at an earlier age (Bird et al., 1989) and have a faster disease progression (Farlow et 
al., 1994) along with more abundant tissue histopathology (Gomez-Isla et al., 1997; Lippa et 
al., 2000; Sakamoto et al., 2002). Similar to sporadic cases of AD first neuropsychological 
symptoms in FAD are early deficits in verbal and figural delayed recall and progressive loss 
of language abilities (Alzheimer's Disease Collaborative Group, 1995; Lopera et al., 1997). 
Additionally executive functions can be affected, consistent with frontal lobe degeneration 
(Raux et al., 2000). A more rapid decline and early symptoms of aphasia and apraxia have 
been more commonly described in FAD than in sporadic AD (Godbolt et al., 2004; Lampe et 
al., 1994; Martin et al., 1991). However, certain PSEN1 mutations have been associated with 
atypical phenotypes including spastic paraparesis (Assini et al., 2003; Kwok et al., 1997; 
O'Riordan et al., 2002), speech production deficits (Kennedy et al., 1995), language 
impairment, and frontal behavioural disturbances (Jimenez-Escrig et al., 2004). Few studies 
have analyzed the longitudinal cognitive changes in FAD. Rosselli et al. (2000), to name one 
of the few, examined 12 patients with FAD (mean age = 49.6 years), 10 patients with sporadic 
AD (mean age = 71.4), and 15 matched normal controls (mean age = 45) with two 
neuropsychological instruments: 1) The Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) neuropsychological test battery, and 2) additional tests of abstraction and 
                                                      
9 Missense mutation: variation in the protein coding sequence which may alter the function of the protein. 
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constructional abilities. Tests were administered three times over a period of 18 months. At 
the first examination, FAD patients were significantly impaired on all measures, except for 
reading of words. While the performance of the normal controls remained almost unchanged 
over the 18 months, the patients with FAD displayed a decline in verbal memory, language, 
constructional and abstraction test. As expected, patients with sporadic AD demonstrated a 
similar pattern of cognitive deterioration, however, decline was faster in FAD than in sporadic 
cases. 
 
Persons in whom the development of AD can be reliably predicted provide a unique 
opportunity for the detection of early markers and the characterization of early stages of the 
disease. Although there have been made advances in the understanding of imaging (Masdeu et 
al., 2005) and biochemical biomarkers (Small, 2002) for AD, neuropsychological testing 
remains the milestone for diagnosing and characterizing the cognitive losses that occur early 
in dementia. In a recent study, Ringman et al. (2005) performed neuropsychological tests on 
51 nondemented at-risk members of 10 mexican families with two distinct PSEN1 mutations. 
Test scores were compared between the 30 mutation carriers and the 21 noncarriers. After 
dividing the subjects into age tertiles, mutation carriers showed lower visuospatial and 
executive function/working memory but not verbal memory or language composite scores. 
However, differences between groups were only found in the oldest tertile, indicating that 
early neuropsychological markers for AD were not detectable decades before the onset of 
FAD. In another preclinical study, Fox et al. (1998) longitudinally assessed asymptomatic 
individuals at risk for FAD. 63 subjects were examined over a 6-year period on current 
intelligence, verbal and visual memory, naming, perception, arithmetic, spelling, psychomotor 
speed and attention. 10 subjects developed symptoms of episodic memory loss and 
subsequently progressed to fulfil criteria for possible or probable AD. Moreover, these 
subjects already had significantly lower verbal memory and performance scores at their first 
assessment, when they were presumably unaffected, and subsequently showed progressive 
decline in multiple cognitive domains. The mean time from first assessment to the appearance 
of symptoms was 2.6 years. Cognitive deficits were accompanied by diffuse cerebral and 
medial temporal lobe atrophy only once subjects were clinically affected. These findings 
suggest, that cognitive decline in FAD is measurable by means of neuropsychology several 
years before clinical onset, and that verbal memory deficits precede more wide spread 
deterioration.  
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By the time first clinical symptoms in AD or even MCI are detectable, a 15 to 30 years long 
period of continuous amyloid plaque deposition and neurofibrillary tangle formation has 
already occurred (Davies et al., 1988; Rumble et al., 1989), and neuronal loss has taken place 
to some extent (Gomez-Isla et al., 1996).  
 
Preclinical Phase                               Clinical Phase
Amyloid Deposition
15 - 30 years                                5 - 10 years
Preclinical Onset of the Disease             Clinical Onset
Time
Cognitive Performance
100%
 
Fig. 3. Neuropathologic events in AD precede clinical onset by 15 to 30 years (Müller-Spahn & Hock, 1999). 
 
Regional cerebral metabolism studies with PET have used 18F-2-deoxy-2-fluoro-D-glucose 
(FDG) as a metabolic marker to detect these changes. MCI patients show decreased 
metabolism in the medial temporal lobe region (de Leon et al., 2001; Nestor et al., 2003). In 
early AD, the most typical pattern is decreased metabolism bilaterally in the parieto-temporal 
association cortex and cingulate gyrus. This pattern corresponds to the degree of 
neuropathologic changes in early AD, more prominent in the medial temporal region, 
cingulate cortex, and in the parietotemporal association cortex (Braak and Braak, 1996; 
Delacourte et al., 1999). Reiman et al. (1996) were the first to report on the prognostic value 
of cortical metabolism studied with PET in healthy elderly people with an increased risk of 
having AD. PSEN1-associated low glucose metabolism has also been found in older 
nondemented Down’s syndrome subjects during brain stimulation (Pietrini et al., 1997). 
Johnson et al. (2001) used single photon emission computed tomography (SPECT) to measure 
regional cerebral perfusion. Asymptomatic PSEN1 mutation carriers showed reduced 
perfusion in comparison to normal noncarrier control subjects in the hippocampal region, 
anterior and posterior cingulated, posterior parietal lobe and anterior frontal lobe. These 
studies indicate, that early AD-related changes in brain metabolism and cerebral perfusion are 
detectable with FDG PET and SPECT, making them the most sensitive neuroimaging 
methods for detecting preclinical markers of AD. However, by the use of an appropriate 
cognitive task and fMRI it may become possible, as we shall see later, to reveal the very first 
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symptoms of AD even before a change of regional glucose metabolism can be detected by 
means of FDG PET. 
 
Medial temporal atrophy is the most sensitive and specific measure to detect early AD 
changes on structural brain imaging. In one study entorhinal cortex volume separated normal 
elderly from those with mild AD with an accuracy of 100% (Killiany et al., 2000). 
Longitudinal studies have shown, that the annual rate of volume change in entorhinal cortex 
distinguishes AD from controls with greater sensitivity and specificity than one time 
measurements (Du et al., 2003). Whereas the annual grey matter loss in normal aging is less 
than 1%, rates as high as 4% occur in early AD (Thompson et al., 2003). The medial temporal 
region is also the first one to be affectd in MCI and as the disease progresses, posterior 
cingulate gyrus and temporo-parietal association cortex are involved (Rusinek et al., 2003; 
Thompson et al., 2003). Schott et al. (2003) assessed the onset of structural change in FAD. 
The brains of 5 presymptomatic FAD patients and 20 controls were annually scanned twice or 
more times. No significant changes were found between patients and controls in baseline 
measures of whole brain, temporal lobe, or ventricular volume, but averaged volumes of both 
hippocampi and the entorhinal cortices were 16.6% lower in patients. Moreover, atrophy rates 
for brain, temporal lobe, hippocampus and entorhinal cortex were significantly increased in 
patients. A linear extrapolation backward suggested that medial temporal lobe atrophy had 
started 3.5 years before onset, when all patients were asymptomatic. In another study, 
Gregory et al. (2005) determined gray matter changes in different cortical regions in genetic 
cases of AD. Genetic mutations were found to influence the degree and regional pattern of 
atrophy, and were associated with greater medial temporal lobe atrophy than sporadic cases, 
suggesting that mutations affecting Aß metabolism selectively increase hippocampal 
degeneration. Cases with mutations in the PSEN1 gene demonstrated additional increased 
frontotemporal atrophy. The authors argue, that this effect may be due to the influence of PS1 
on tau phosphorylation and metabolism.  
Taken together, these studies suggest, that increased medial temporal lobe atrophy is 
an early feature of AD, and that, pathological atrophy probably is occurring several years 
before the clinical onset of the disease. 
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2. Goals and hypotheses of the two experimental studies 
 
The purpose of the two studies reported in this doctoral thesis was to investigate genetic 
influences on memory performance, memory-related brain activity and neuroanatomy. 
Furthermore, we tried to detect earliest preclinical markers of AD decades before the clinical 
onset of the disease. 
 
2.1. Effects of Apolipoprotein E (APOE) variants on memory 
 
In the first study we examined the effects of apolipoprotein E allelic variants in young and 
healthy subjects. Detrimental effects of APOE4 on cognition and brain physiology have been 
detected in middle-aged to elderly nondemented and healthy subjects. However, it is unclear 
whether the reported disadvantages of APOE4 were related to its effects on normal 
neurophysiologic variability in these subjects, or whether they were strongly connected to a 
possibly ongoing AD-related neuropathology. Because neurofibrillary tangle formation and 
amyloid plaque deposition in the MTL start 15-30 years prior to the clinical onset of late-
onset sporadic forms of AD, it is conceivable that young human subjects in their twenties are 
devoid of any such pathology, therefore creating ideal premises for a pathology-independent 
measurement of APOE4 effects on normal memory neurophysiology. By combining 
neuroimaging and episodic memory tasks tailored to hippocampal function we addressed the 
following questions: 
 
• First, does the APOE ε4 allele has an effect on episodic memory performance in 
young and healthy subjects ?  
 
• Second, do ε4 carriers show altered brain activations in brain areas that mediate 
episodic memory and that are the first areas to be affected by neuropathological 
changes in AD ?  
 
• Third, is potentially altered brain activity in ε4 carriers specific for episodic memory 
or any other cognitive function ? 
 
• Fourth, do ε4 carriers show altered brain morphology, especially in the hippocampus ? 
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2.2. Effects of the C410Y mutation of the Presenilin 1 (PSEN1) gene on memory 
 
In the second study we sought to detect early preclinical signs of AD in mutation carriers of 
the FAD-causative gene PSEN1. Since FAD patients present with an early age of onset and a 
faster and massive progression of AD-related neuropathology, compared to the sporadic AD 
cases, it is conceivable that early signs of the disease might be detectable already decades 
before the fully clinical presentation of AD. As yet, preclinical signs of AD have been 
detected some years prior to the onset of the disease in MCI and prodromal AD patients in 
studies using neuropsychological assessments and neuroimaging meausures of brain 
metabolism and structural changes. For a preventive treatment of the disease, however, it is of 
great importance to detect first disease-related changes as early as possible. Hitherto FDG-
PET was the most sensitive method for the early detection of abnormal brain metabolism. 
There are utterly no studies using functional magnetic resonance imaging to detect preclinical 
signs of AD in young subjects. We combined neuropsychological testing, functional and 
structural MRI and sensitive hippocampus-dependent episodic memory tasks to detect earliest 
AD-related changes in young PSEN1 muation carriers. We hypothesized that: 
 
• a) early changes in memory-related hippocampal activity should be detectable decades 
before clinical onset of the disease in young AD-causative gene mutation carriers, 
because PSEN1 mutation carriers might suffer from early deposits in MTL structures 
elicited by the presence of the mutation since birth 
 
• b) according to the ‘compensatory hypothesis’ young PSEN1 mutation carriers should 
exhibit enhanced hippocampal and/or neocortical memory-related brain activity when 
performing sensitive episodic memory tasks to achieve comparable performance levels 
as noncarriers 
 
• c) young PSEN1 mutation carriers will not show deficits in cognitive functions 
assuming that the early preclinical regional neuronal dysfunction can be compensated 
to keep performance at normal levels 
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The apolipoprotein E (APOE) ε4 allele is the major genetic risk factor for Alzheimer’s 
disease (AD), but an effect on memory in the absence of AD neuropathology is unknown. 
We found an association of APOE ε4 with better episodic memory compared to APOE ε2 
and ε3 in 340 young, healthy persons. Neuroimaging was performed in a subset of 34 
memory-matched individuals to study genetic effects on memory-related brain activity 
independently of differential performance. Ε4 carriers decreased brain activity over 
three learning runs, while ε2 and ε3 carriers increased activity. This smaller neural 
investment of ε4 carriers into learning reappeared during retrieval: ε4 carriers 
exhibited reduced retrieval-related activity with equal retrieval performance. APOE 
isoforms had no differential effects on neuropsychological performance, brain volumes, 
and brain activity related to working memory. We suggest that APOE ε4 is associated 
with good episodic memory and an economic use of memory-related neural resources in 
healthy humans.  
The APOE gene and memory 
  32 
Introduction 
The APOE ε4 allele (APOE4) has an extensive record of deleterious effects on several 
biological processes. The possession of at least one ε4 allele increases the risk of AD 
(Saunders et al., 1993) threefold, presumably through an association of APOE4 with the 
pathologic hallmarks of AD, i.e., amyloid plaque deposition and neurofibrillary tangle 
formation (Bennett et al., 2003; Tiraboschi et al., 2004). In contrast, the possession of an ε2 
allele appears to confer a protective effect against AD and AD-related neuropathology 
(Corder et al., 1994). Moreover, APOE2 is associated with a reduced decline in episodic 
memory in elderly persons (Wilson et al., 2002), while APOE4 exerts detrimental effects in 
middle aged and elderly subjects on memory performance (Baxter et al., 2003; Bondi et al., 
1995; Hyman et al., 1996), visual attention (Greenwood et al., 2000), executive functions 
(Rosen et al., 2005), memory-related brain activity (Bondi et al., 2005; Bookheimer et al., 
2000) and resting brain glucose metabolism (Reiman et al., 2002b). APOE4 has also been 
experimentally related to impaired hippocampal plasticity (Levi et al., 2003) and lower 
density of dendritic spines (Ji et al., 2003) in aged transgenic mice and to increased 
neurotoxicity (Qiu et al., 2003) in vitro.  
Although the frequency of the APOE4 allele in humans is low (15% in Caucasians), 
studies in primates suggest that it is the ancestral allele (Finch and Sapolsky, 1999). The 
common (75% in Caucasians) and uniquely human APOE3 allele appeared as a mutation and 
its frequency increased during human evolution (Finch and Sapolsky, 1999). Because the 
APOE4 allele has been related to several deleterious biological effects, the question arises 
why it existed in the first place (Finch and Sapolsky, 1999). From the evolutionary standpoint, 
a possible advantageous effect of the APOE4 allele in childhood and early adulthood could 
explain its existence and further persistence in humans. Support for this notion comes from 
studies where APOE4 has been associated with higher IQ scores (Yu et al., 2000), a higher 
educational level (Hubacek et al., 2001), a reduced cardiovascular response to experimentally 
induced stress (Ravaja et al., 1997), and a protective effect against spontaneous abortion 
during embryogenesis (Zetterberg et al., 2002). 
It is conceivable that the effects of the APOE isoforms in AD may be distinct from their role 
in normal memory. As yet, an effect of the APOE isoforms on normal human memory is 
unknown. To address this issue, we combined human genetics with memory assessments and 
functional and structural neuroimaging and mapped genetically transmitted differences in 
normal memory performance onto brain functions. Behavioral effects of the APOE gene’s 
three allelic variants on learning and memory were assessed in a large sample of 340 healthy 
The APOE gene and memory 
  33 
young subjects (years of age, M: 22.8, SD: 4.0). Neurophysiologic effects of the APOE gene’s 
allelic variants were examined with functional magnetic resonance imaging (fMRI) in 34 of 
the 340 original subjects. The 34 subjects underwent one fMRI experiment on episodic 
memory (Fig. 1) and a second fMRI experiment on working memory. The examination of 
both episodic and working memory allowed us to determine the specificity of the genetic 
effects on memory. 
 
Materials and Methods 
Subjects. A description of the large subject sample and the genotyping procedures is provided 
elsewhere (de Quervain et al., 2003). For the APOE isoforms, 40 subjects had either the ε2/ε2 
or the ε2/ε3 alleles, 214 the ε3/ε3 alleles, 80 the ε3/ε4 alleles and 6 subjects had the ε4/ε4 
alleles.   
Of the 34 subjects (years of age, M: 22.3, SD: 2.53) who participated in the fMRI 
experiments, 11 carried the ε2/ε3 genotype, ten the ε3/ε3 genotype, and 13 the ε3/ε4 
genotype. Importantly, these subjects were drawn from the large sample such that no 
statistically significant differences occurred between groups for age, years of education, the 
His452Tyr polymorphism of the 5-HT2a receptor encoding gene (de Quervain et al., 2003), 
and the 5-min words recall performance in the previously applied verbal memory test (de 
Quervain et al., 2003) (Table 1). The reason why we matched the three genotype groups for 
memory performance was to eliminate performance-related brain activity differences in order 
to sample only genetic effects on brain activity. The subjects reported neither past nor current 
psychiatric or neurological problems and denied taking illegal drugs or prescription 
medication. Their anatomical MRI scans showed normal brain structures. All subjects gave 
written informed consent to participate in the study after the nature and possible consequences 
of the study had been explained. The experiments were approved by the ethics committee of 
the Kanton Zurich. 
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Experimental procedure – large sample. The 340 subjects viewed six sets of words, each set 
consisting of five semantically unrelated nouns. Subjects were instructed to learn the five 
words of a set for immediate recall. The immediate recall followed the presentation of each 
word set. Five minutes following the completion of the six word sets, subjects engaged in a 
surprise delayed recall test of the 30 learned nouns (de Quervain et al., 2003). 
Experimental procedure – small sample. Subjects underwent two fMRI experiments, one on 
episodic memory and the other on working memory. Trials were blocked in each fMRI 
experiment. Subjects practiced all fMRI tasks prior to scanning. The same stimuli were used 
for all subjects to reduce inter-subject variance caused by stimulus-generated effects. 
Responses were collected with a response box that subjects held in their dominant hand. 
fMRI Experiment on episodic memory – Encoding. We presented 16 face-profession 
pairs for associative learning, 16 faces for single face learning, and 24 head contours without 
physiognomy in the visual baseline condition (Fig. 1). 
 
Figure 1. Study design. Left side (encoding fMRI time-series): Examples of stimuli presented for associative 
learning, for single face learning and for the visual baseline task. Each stimulus appeared once in each run. The 
order of stimuli was constant across runs. Right side (retrieval fMRI time-series): Examples of stimuli presented 
for associative retrieval, for single face recognition, for new face detection and for the visual baseline task. Alex 
Kayser granted us permission to use faces from his book “Heads”, 1985, New York: Abbeville Press. 
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The face profession-pairs and the single faces were learned over three consecutive learning 
runs (three separate fMRI time series) to monitor genotype-induced brain activity differences 
during the progressively deeper encoding of the material. The instruction for associative 
learning of the face-profession pairs was to imagine the presented person acting in a scene of 
the written profession. Subjects answered by button press whether they found it easy or hard 
to imagine a scene. The imagination of a scene automatically leads to the establishment of 
semantic person-occupation associations and activates the hippocampal formation (Degonda 
et al., 2005). Importantly, subjects were requested to imagine the same scene for a given face-
profession pair during runs 2 and 3 as during run 1. This additional retrieval component in 
runs 2 and 3 was to enhance potential memory-related differences between genotype groups. 
The instruction for the learning of single faces was to decide whether a face was pleasant or 
unpleasant. This task yields a semantic encoding of faces. The visual baseline task was to 
decide whether the area of the left or right ear was larger. The sequence of conditions within 
the fMRI time-series was counterbalanced across subjects. Each learning condition consisted 
of four blocks. A block contained four trials of 6 s each. The baseline condition consisted also 
of four blocks. Here, a block contained six trials of 4 s each. Consequently, each task block 
took 24 s. An instruction slide announced each task block. 
fMRI Experiment on episodic memory – Retrieval. We applied a single fMRI time-
series for the retrieval of the previously learned face-profession associations and faces. This 
time-series included an associative retrieval condition, a face recognition condition, a new 
faces (distracter faces) detection condition and the same visual baseline condition that was 
used for the encoding time-series (Fig. 1). For the retrieval of the associations, the previously 
presented faces were shown again (without the professions) as retrieval cues with the 
instruction to recall each person’s occupation and to indicate the superordinate professional 
category by button press: academic or workman. For face recognition/new face detection, old 
(studied) and new faces were presented with the instruction to indicate by button press 
whether a face was fully recollected, appeared just familiar or was completely new (Tulving, 
1985). The sequence of conditions within the fMRI time-series was counterbalanced across 
subjects. All conditions, except for the visual baseline condition (see above), consisted of four 
blocks, each block including four trials of 6 s each. All task blocks took 24 s and were 
announced by an instruction slide.  
fMRI Experiment on working memory. The experiment included one fMRI time-
series with a 2-back task for the assessment of working memory and a baseline task (‘x-
target’) for the assessment of concentration. The 2-back task required subjects to respond to a 
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letter repeat with one intervening letter (e.g. S – f – s – g). The ‘x-target’ task required 
subjects to respond to the occurrence of the letter ‘x’. 
Each task was given in five blocks of 26 s each. Blocks were announced by an instruction 
slide. Stimuli were 50 upper- or lowercase letters typed in black on a white background. 
Thirteen upper- or lowercase letters were presented per block for the duration of 2 s each.  
Data acquisition. MR measurements were performed on a 3T Philips Intera whole 
body MR scanner equipped with an eight-channel Philips SENSE head coil. Functional data 
were obtained from 32 transverse slices parallel to the AC-PC plane covering the whole brain 
with a measured spatial resolution of 2.8 x 2.8 x 4 mm3 (acquisition matrix 80 x 80) and a 
reconstructed resolution of 1.7 x 1.7 x 4 mm3. Data were acquired using a SENSE-sshEPI 
(Schmidt et al., 2005) sequence with an acceleration factor of R = 2.0. Other scan parameters 
were TE = 35 ms, TR = 3000 ms, θ = 82°. A standard 3D T1-weighted scan was obtained for 
anatomical reference with a measured spatial resolution of 1 x 1 x 1.5 mm3 (acquisition matrix 
224 x 224) and a reconstructed resolution of 0.9 x 0.9 x 0.8 mm3, TE = 2.3 ms, TR = 20 ms, θ 
= 20°. A 2D T1-weighted inversion-recovery anatomical scan, oriented perpendicularly to the 
long axis of the hippocampus, was obtained for hippocampal and parahippocampal volumetry 
over 33-39 slices with a measured spatial resolution of 0.5 x 0.6 x 1.5 mm3 (acquisition matrix 
400 x 320) and a reconstructed spatial resolution of 0.4 x 0.4 x 1.5 mm3, TE = 15 ms, TR = 
4200 ms, θ = 20°, IR delay 400 ms, and no interslice gaps. 
Analysis of functional MRI data. Image pre- and postprocessing and the statistical 
analyses were performed with SPM2 (http://www.fil.ion.ucl.ac.uk/spm). Standard 
preprocessing procedures were applied, i.e., realignment, normalization and spatial smoothing 
(8 mm) (Friston et al., 1995a). On the single subject level, data were analyzed according to 
the fixed effects model (SPM2). The six head movement parameters were included in the 
model as confounding factors. Data were high-pass filtered with a specific filter-value for 
each fMRI time series. This value was determined according to ‘2*SOA*TR’. On the second 
level, within-subject contrasts were entered into random effects analyses (ANOVAs, T-tests, 
SPM2) which account for variance between subjects (Friston et al., 1995b). We also 
computed correlations between the within-subject encoding contrasts (learning run1 – run3) 
and behavioral measures (simple regression, SPM2). Thresholds were set at a p < 0.001 level, 
uncorrected for multiple comparisons; exceptions were made for the region of interest, i.e., 
the hippocampus, and are indicated where applicable. 
Analysis of anatomical MRI data. Based on the 3D-T1-weighted structural MRI 
images which covered the whole brain, volumes of the total gray and white matter were 
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computed with SPM2. Images were first normalized into the MNI T1 template using a 
standard bounding box and then segmented into gray matter, white matter and cerebrospinal 
fluid. Standardized gray and white matter volumes were then multiplied by the determinant of 
the linear transformation matrix to obtain gray and white matter volumes in cm3. Based on the 
2D-T1-weighted high resolution structural MRI images, two independent raters (A.B. and 
H.M.) manually delineated the hippocampal formation (Henke et al., 1999a) (CA regions, 
dentate gyrus and subiculum, excluding the fimbria) and the parahippocampal gyrus using the 
software Pmod (http://www.pmod.com.). Cerebrospinal fluid was carefully excluded resulting 
in conservative volume estimates. Raters relied on descriptions of anatomical landmarks and 
subdivisions of the MTL as described by Insausti et al. (1998) and Duvernoy (1998). Inter-
rater reliabilities ranged between r = 0.8 and 0.98. ANOVAs with APOE genotype and sex as 
independent variables were computed to determine group differences in brain volumes. 
Thresholds were set at p < 0.05 level, uncorrected for multiple comparisons (6 subjects 
excluded from this analysis because of data loss).  
Neuropsychology. Memory functions were assessed with the Wechsler Memory Scale 
Revised (Härting et al., 2000) in German and with and a difficult verbal paired-associates 
word learning test (VAT) (Henke et al., 1999b). Intelligence was measured with the Hamburg 
Wechsler Intelligence Test (Tewes, 1991). Spatial thinking abilities were tested with the Luria 
Mental Rotation Test (Christensen, 1979). Executive functions were assessed with a verbal 
(S-Words) and nonverbal (5-Point) fluency task (Regard et al., 1982), with the Kramer Card 
Sorting Test (Kramer, 1970), which measures concept finding and shifting abilities, and with 
the Stroop Test (Stroop, 1935), which measures the suppression of interference. ANOVAs 
with the APOE genotype as an independent variable were computed to determine group 
differences in cognitive performance. Thresholds were set at p < 0.05 level, uncorrected for 
multiple comparisons (one subject excluded from this analysis because of non-compliance). 
 
 
Results 
Behavioral results – large sample 
The APOE4 carriers, compared to non-carriers, exhibited better performance in the 
delayed, but not the immediate recall of the 30 studied words (odds ratio = 1.6, P = 0.009; 
Fig. 2A). This result remained significant after excluding the six homozygous ε4 allele 
carriers from the analysis (odds ratio = 1.6, P = 0.023). Moreover, multiple linear regression 
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analysis revealed a significant linear relationship between the presence of no, one, or two ε4 
alleles and the delayed recall of words (βstandardized= 0.118, P = 0.023; Fig. 2B).  
 
 
Figure 2.  APOE effects on verbal memory in 340 subjects. a) Forward and backward logistic regression 
analysis after median split for the 5-min recall of words (dependent variable). Factors significantly associated 
with better memory performance (> median of 8) were female sex, good immediate recall (IR) and the APOE ε4 
allele, while age, education (Edu) and the H452Y substitution of the HTR2a gene were not. Dotted line indicates 
odds ratio of 1. Error bars reflect 95% confidence interval of odds ratio per independent variable. b) Multiple 
forward and backward linear regression with the 5-min recall performance as dependent variable adjusted for 
sex, education, immediate recall and the H452Y substitution of the HTR2A gene. Dots depict mean, bars depict 
standard error of mean (SEM).  
 
These performance differences in the delayed recall test cannot be attributed to differences in 
working memory, motivation, or attention because the immediate recall of words was 
comparable between the genotype groups. To minimize the possibility of a type I error due to 
non-random genetic heterogeneity of the study sample, we computed the genetic structure of 
the population by genotyping each subject for 55 unlinked single nucleotide polymorphisms 
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located mostly in non-genic regions and distributed over all autosomes. Structured association 
analysis (Pritchard and Rosenberg, 1999) revealed a low allele-frequency divergence in our 
population (Kullback-Leibler distance = 0.15) and excluded non-random, gross genetic 
heterogeneity as a potential source of false positivity. 
 
Behavioral results – small sample 
Response latencies decreased significantly from learning run1 to run3 within each 
APOE group for both faces and face-profession pairs supporting effective learning in each 
APOE group. APOE group differences in response latencies occurred neither within nor 
between runs (Table 2). The number of ‘easy’ (to imagine) answers during associative 
learning increased over learning runs for each APOE group (Table 2; effect did not quite 
reach significance in APOE ε3/ε4 carriers with p = 0.06). This facilitation of imagining a 
scene was also indicative of effective learning over runs. There were no APOE group 
differences in the number of ‘easy’ answers within or between runs. The number of ‘pleasant’ 
decisions for the single faces remained constant over the three learning runs for each APOE 
group. APOE groups did not differ in the number of given ‘pleasant’ answers within or 
between runs (Table 2). 
Retrieval accuracies and response latencies for faces and face-profession associations 
were statistically equal between APOE groups (Table 2).  
In the working memory experiment, neither accuracy nor reaction latency differed 
significantly between APOE groups for the ‘x-target’ and the 2-back task (Supplemental 
Table S1). 
Performance measures acquired during the neuropsychological examination of the 34 
subjects - i.e., measures of memory, intelligence, spatial cognition and executive functions - 
were also statistically equal across APOE groups (Supplemental Table S2). 
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Imaging results – small sample 
The analysis of the imaging data focused on the medial temporal lobe (MTL). One-sample T-
tests including all 34 subjects revealed robust bilateral hippocampal activation for face-
profession associative learning and for single face learning confirming that our tasks activated 
the hippocampus reliably in the present subjects (data not shown). One-way ANOVAs 
(SPM2) with the APOE genotype as an independent variable were followed by two sample T-
tests between the ε3/ε4 and ε2/ε3 carriers. We directly compared the ε3/ε4 and ε2/ε3 carriers 
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because the ε4 and the ε2 allele might not only confer opposite effects on the risk of AD 
(Corder et al., 1994) but also on the normal memory-related physiology. Therefore, we were 
expecting to see the largest brain activity differences between the ε3/ε4 and the ε2/ε3 carriers.  
Significant differences in signal change from learning run1 to run3 in both the 
ANOVA and the post-hoc t-tests between the ε3/ε4 and the ε2/ε3 carriers were located in 
bilateral hippocampus during associative learning and in the left hippocampus during single 
face learning (Table 3, Fig. 3A).  
 
 
 
Figure 3. APOE effects on learning-related brain activity in 34 subjects. a) Left panel: One-way ANOVA 
showing APOE effect on the right and left hippocampal signal change from run1 to run3 of associative learning 
(run3 - run1). Columns indicate mean-corrected parameter estimates, bars depict SEM parameter estimates. 
Right panel: Larger right and left hippocampal signal decrease during associative learning from run1 to run3 in 
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APOE ε3/ε4 versus APOE ε2/ε3 carriers displayed as color-coded statistical parametric t-map overlaid on 
Montreal Neurologic Institute (MNI) anatomical scan. b) Simple regression between left hippocampal signal 
difference between runs (run1 – run3) during associative learning and the retrieval success computed for APOE 
ε3/ε4 (left panel) and APOE ε2/ε3 carriers (right panel).  
 
Further effects were situated in neocortical areas, namely the left orbital gyrus and a left 
posterior middle temporal region during associative learning and in the middle frontal gyrus 
during single face learning (Table 3). 
While the ε3/ε4 carriers decreased their learning-related hippocampal and neocortical 
activity from the first to the third learning run, the ε2/ε3 and the ε3/ε3 carriers increased their 
learning-related hippocampal and neocortical activity from the first to the third learning run 
(Fig. 4). 
 
Figure 4. Whole brain activity differences between learning runs 1 and 3 for each APOE group. Sagittal, coronal 
and horizontal SPM2 through-projections of brain regions that exhibited a significant signal decrease (run1- 
run3) or signal increase (run3 – run1) during associative learning (left side) and single face learning (right side).   
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These differences in the slope of activity changes over learning runs were not caused by 
unequal starting levels of learning-related activity between groups, because there were no 
significant brain activity differences between APOE groups in the first learning run (data not 
shown).  
Next, we computed correlations between the signal change from learning run1 to run3 
and the number of correctly remembered associations or faces in order to determine whether 
the slope of learning-related brain activity was related to retrieval success. These correlations 
were positive (i.e., the more signal decrease during learning, the better the retrieval 
performance) for the ε3/ε4 carriers, but negative (i.e., the more signal increase during 
learning, the better retrieval performance) for the ε2/ε3 carriers within the left hippocampus 
(ε3/ε4: r = 0.75; ε2/ε3: r = - 0.78; Fig. 3B) and several left and right prefrontal areas.  
During retrieval, the ε3/ε4 carriers exhibited sparser retrieval-related neural 
recruitment than the ε2/ε3 carriers in spite of their equivalent retrieval success. The 
comparison of the retrieval of face-profession associations with the retrieval of single faces 
isolates brain activity underlying the retrieval of associations alone. In this comparison, the 
ε3/ε4 carriers exhibited weaker activity compared to the ε2/ε3 carriers in the right 
hippocampus and the left fusiform gyrus (Table 3). In the comparison of single face retrieval 
with baseline, the ε3/ε4 carriers exhibited weaker activity increases compared to the ε2/ε3 
carriers in the right middle and superior frontal gyri and in the right precuneus (Table 3).  
The reported brain activity differences between APOE groups were specific to 
episodic memory because the working memory fMRI experiment yielded no MR signal 
differences between the ε2/ε3 and the ε3/ε4 carriers.  
 
 
 
The APOE gene and memory 
  44 
 
The APOE gene and memory 
  45 
To determine whether APOE group differences in brain activity resulted from interindividual 
differences in the volume of gray or white brain matter, we performed volumetric analyses of 
the subjects’ brain structures. Both automated whole brain gray and white matter 
segmentation (SPM2) (Ashburner and Friston, 2000) and manual volume measurements of 
the hippocampal formation and the parahippocampal gyrus yielded comparable volumes 
between the three APOE groups (Table 4).  
 
 
Discussion 
APOE4 is the major genetic risk factor for AD. Studies in primates suggest that 
APOE4 is the ancestral allele (Finch and Sapolsky, 1999). Its existence and further persistence 
– though at a low frequency - in humans might be explained by an advantageous effect of 
APOE4 in early adulthood. Here, we report an association of APOE4 with better memory 
performance and with less learning- and retrieval-related brain activity compared to APOE2 
and APOE3 in young and healthy human subjects. 
In particular, we found a reverse relationship of learning/retrieval success with brain 
activity levels in APOE4 compared to APOE2 carriers. Although the starting levels of 
learning-related brain activity were comparable between APOE groups, ε3/ε4 carriers 
decreased their learning-related hippocampal and neocortical activity during the progressively 
deeper encoding of the material, while the ε2/ε3 and the ε3/ε3 carriers increased their 
learning-related brain activity (Fig. 4). This disparity in the learning-related brain activity 
slopes was not related to group differences in the cognitive processes applied during learning 
because all performance measures collected during the learning runs were statistically equal 
between APOE groups (Table 2). We therefore suggest that the APOE ε4 allele is associated 
with a more economic use of learning-related hippocampal and neocortical resources.  
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The question arises of whether the group differences in brain activity slopes reflect a 
differential neurophysiology underlying episodic memory or another form of memory which 
is simultaneously active during the learning runs. The repeated exposure to material does not 
only evoke retrieval (from previous exposure) and re-encoding processes in the realm of 
episodic memory but also priming. Priming is a form of implicit/nondeclarative memory that 
involves a facilitation of the ability to identify, produce or classify an item as a result of a 
previous encounter with that item or a related item (Schacter et al., 2004). Priming is often 
associated with accelerated information processing (shortening of reaction latencies) and 
decreasing neural activity over repeated exposures, as observed in our APOE4 group. It could 
therefore be speculated that the differential hippocampal activity slopes over learning runs 
reflected priming more than episodic memory. We found that neither of the APOE groups 
exhibited a significant correlation of medial temporal activity slopes with the shortening of 
reaction latencies from run1 to run3 (data not shown). Instead, medial temporal activity slopes 
were correlated with retrieval success for both faces and face-profession associations. 
Importantly, these correlations were positive - i.e., the more signal decrease over runs, the 
better retrieval performance - for the ε3/ε4 carriers, but negative – i.e., the more signal 
increase over runs, the better retrieval performance - for the ε2/ε3 carriers (Fig. 3B). These 
findings indicate that medial temporal activity changes over learning runs were related to 
episodic memory. At the same time, these correlations also underscore the reverse 
relationship between episodic memory and hippocampal activity levels in APOE4 versus 
APOE2 carriers: While a large signal increase denoted the good learner among the APOE2 
carriers, a large signal decrease during repeated learning characterized the good learner 
among the APOE4 carriers. Together, APOE4 carriers engaged less neural resources into the 
complete learning process compared to APOE2 carriers which points to a more economic use 
of neural resources. It is interesting that steeper medial temporal activity slopes over repeated 
face learning have also been found for healthy subjects compared to patients with an amnestic 
mild cognitive impairment (Johnson et al., 2004). Thus, it appears that economic use of 
learning-related medial temporal resources characterizes a well functioning episodic memory 
system.  
We again observed a more economic use of memory-related neural resources in 
APOE4 carriers at the time of retrieval. APOE4 carriers invested fewer hippocampal and 
neocortical activity into the retrieval process than APOE2 carriers, while achieving an 
equivalent retrieval success (Table 3). This finding suggests that task demands were higher on 
the APOE2 than the APOE4 carriers – a finding that is intuitive given the better retrieval 
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performance in the APOE4 carriers in the large and non-matched sample of 340 subjects. 
Although we had matched participants of the fMRI study for memory performance, task 
demands might still have been higher on the APOE2 than the APOE4 carriers. It has been 
demonstrated for a variety of cognitive tasks that increasing task demands are associated with 
an increase in the spatial extent and the magnitude of brain activity in the task-specialized 
neural network (Carpenter et al., 1999; Just et al., 1996). Patients with an amnestic mild 
cognitive impairment exhibited larger memory-related activity enhancements within the 
medial temporal lobe (Dickerson et al., 2004) compared to healthy individuals. In addition, 
neuroimaging studies have shown that the brains of high performers or people with much 
practice work more efficiently (less activity with better task performance) than the brains of 
lower performers or people with less practice (Haier et al., 1992a; Haier et al., 1992b; 
Neubauer et al., 2005). We conclude, therefore, that medial temporal activity may be elevated 
in response to increasing task demands caused by either an objective increase in task 
difficulty or a subjective increase in task difficulty due to less practice or less favorable 
genetic or neurophysiologic setting.  
It should be noted that our neuroimaging APOE groups were statistically equal in 
terms of neuropsychological test performance (Table S2) and gray and white matter volumes 
(Table 4) - particularly hippocampal and parahippocampal volumes. It is, therefore, unlikely 
that the performance and imaging results were biased by morphological or cognitive 
differences between APOE groups. Moreover, brain activity differences between APOE 
groups were found only for episodic memory, not working memory. The three APOE groups 
differed neither in performance (Table S1) nor brain activity levels on the working memory 
task. 
The more economic use of neural resources in APOE4 carriers concurs with 
advantageous effects of the APOE4 allele on normal neurophysiologic functioning in young 
animals. Hippocampal long-term potentiation (LTP) is enhanced at a younger age in knock-in 
mice lacking mouse APOE, but instead expressing human APOE4 (Kitamura et al., 2004). 
This LTP enhancement is age-dependent and disappears in adult knock-in mice. Moreover, 
APOE4, but not APOE3, stimulates the transcriptional activity of cAMP-response element-
binding protein (CREB) by activating the extracellular signal regulated kinase (ERK) cascade 
in rat primary hippocampal neurons (Ohkubo et al., 2001). The influence of APOE4 on this 
memory-related pathway may provide an explanation for the beneficial effect of APOE4 on 
human memory in young adults. On the other hand, there is evidence that APOE4 alters 
intracellular calcium homeostasis which might ultimately lead to neuronal damage (Qiu et al., 
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2003). One may speculate that a sustained APOE4-related neuronal calcium increase, which is 
related to improved memory performance at a young age, finally induces age-associated 
neuronal damage. 
Alternatively, the APOE4-associated cognitive impairment and abnormal brain 
activity/metabolism found in middle-aged and elderly subjects might be a consequence of the 
continuous deposition of amyloid plaques and neurofibrillary tangles, which are associated 
with dysfunction, deafferentation, and degeneration of neurons in the long course of AD. The 
deposition of amyloid plaques and neurofibrillary tangles has been related to the presence of  
the APOE4 allele (Bennett et al., 2003; Tiraboschi et al., 2004). Importantly, these 
neuropathological changes precede the clinical diagnosis of AD by 30-50 years (Braak and 
Braak, 1996; Delacourte et al., 1999; Ohm et al., 1995). A single copy of the APOE4 allele in 
middle-aged and elderly persons with normal memory performance was associated with 
lowered parietal and temporal metabolism, which predicted cognitive and metabolic decline 
after two years of longitudinal follow-up (de Leon et al., 2001; Small et al., 2000). Moreover, 
elderly APOE4 carriers, compared to APOE3 carriers, exhibited increases in brain activity in 
response to verbal (Bookheimer et al., 2000) and picture (Bondi et al., 2005) learning 
presumably to compensate for AD-related preclinical neuropathology. Indeed, the greater 
their brain activity increase was, the greater was their memory decline during the following 
two years (Bookheimer et al., 2000). Thus, it appears that the brain activity abnormalities in 
middle-aged and elderly APOE4 carriers reflect on-going pathophysiologic processes of AD. 
Because of the long preclinical course of AD (Braak and Braak, 1996; Delacourte et al., 1999; 
Ohm et al., 1995), a direct effect of the APOE isoforms on normal memory-related 
neurophysiology in the absence of disease can only be studied in young subjects.  
In conclusion, we suggest that the APOE4 allele is associated with positive effects on 
episodic memory in healthy individuals. Its association with cognitive impairment and 
abnormal brain activity later in life is probably mediated by AD-related neuropathology. 
Future studies need to address a potential link between the APOE4 allele’s beneficial effects 
on the normal memory neurophysiology and its role as a risk factor for AD.  
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Summary 
Presenilin 1 (PSEN1) mutations cause familial Alzheimer’s disease (FAD) in an 
autosomal dominant mode of transmission. PSEN1 mutation carriers exhibit the normal 
course of cognitive deterioration seen in sporadic Alzheimer’s disease (AD) with first 
deficits in episodic memory. However, FAD is associated with a younger age of onset and 
a faster disease progression compared to sporadic AD. Here, we sought to determine 
preclinical signs of AD decades before the clinical onset of the disease. Five nondemented 
members of a family with a PSEN1 mutation (C410Y) as well as 21 controls from non-
AD families were examined, using functional and structural magnetic resonance 
imaging and neuropsychological assessments. A 20 year old and a 45 year old family 
member carried the C410Y mutation on the PSEN1 gene. The age of AD diagnosis in 
this family is around 48 years. Both mutation carriers exhibited a selective impairment 
(> 2 SDs) in tasks of episodic memory. We found an enhanced neural recruitment, 
compared to controls and family members without the mutation, in a memory-related 
network during both episodic learning and retrieval in the 20 year old mutation carrier. 
The 45 year old mutation carrier exhibited decreased brain activity in memory-related 
areas during episodic learning and retrieval. The amplified activity in the 20 year old 
subject might reflect a compensatory effort to overcome preclinical memory dysfunction 
induced by accumulating AD pathology, while activity reductions in the 45 year old 
subject might reflect gross neural dysfunction in a more advanced stage of 
neuropathology. We suggest that Alzheimer-related memory dysfunction can be 
identified 30 years before AD diagnosis in individual subjects with the use of functional 
neuroimaging and memory tasks tailored to MTL function. 
 
 
Keywords: Presenilin 1, Alzheimer’s disease, fMRI, memory, hippocampus 
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Introduction 
Familial Alzheimer’s Disease (FAD) is transmitted in an autosomal dominant manner and has 
been associated with mutations in the amyloid precursor protein gene (APP) on chromosome 
21 (Goate et al., 1991), the presenilin 1 gene (PSEN1) on chromosome 14 (Alzheimer's 
Disease Collaborative Group, 1995; Sherrington et al., 1995) and the presenilin 2 gene 
(PSEN2) on chromosome 1 (Levy-Lahad et al., 1995; Rogaev et al., 1995). Approximately 
55% of all FAD cases are caused by mutations in the PSEN1 gene (Cruts and van 
Broeckhoven C., 1998). Today, more than 50 missense mutations of the PSEN1 gene are 
known with an age of onset of AD ranging from 25 years to 64 years (Czech et al., 2000). The 
first clinical signs in early AD are episodic memory deficits and declines in executive and 
visuospatial functions. In comparison to sporadic forms of AD (SAD), familial cases show 
initial clinical symptoms at an earlier age and have a faster disease progression along with 
more abundant tissue histopathology (Gomez-Isla et al., 1997; Lippa et al., 2000; Sakamoto et 
al., 2002). The neuropathological course of AD is characterised by a broad cortical amyloid 
beta (Aß) deposition and tau pathology (neurofibrillary tangles) starting prominently in the 
medial temporal lobe (MTL) region 15-30 years prior to clinical symptoms, then spreading 
throughout the neocortex in later stages of the disease (Braak and Braak, 1996; Delacourte et 
al., 1999; Price et al., 1991). It is of great importance that preventive therapies can be 
developed which might slow down or even stop the process of neuropathological 
deterioration. For an optimal treatment of the disease the availability of valid 
neuropsychological, neuroanatomical, neurophysiological or biological markers for the early 
diagnosis is mandatory.  
As yet, one of the most sensitive methods in the early diagnosis of AD is 
fluorodeoxyglucose positron emission tomography (FDG PET). Metabolic changes have been 
detected in cognitively normal carriers of the apolipoprotein E ε4 allele (APOE4), a risk allele 
for AD (de Leon et al., 2001; Reiman et al., 2004; Reiman et al., 2005; Reiman et al., 1996; 
Small et al., 2000). Abnormally low rates of glucose metabolism were found in the same brain 
regions as in patients with probable AD, i.e. in posterior cingulate, parietal, temporal and 
prefrontal cortex, even in young adulthood (Reiman et al. 2004). Notably, in some cognitively 
healthy subjects at risk for AD, cerebral metabolism at rest was normal, but a stress test 
paradigm (audio-visual stimulation) revealed temporo-parietal metabolic abnormalities 
(Pietrini et al., 1997), i.e. affected neurons showed some malfunction when activated by an 
appropriate task.  
Task-induced activity alterations in persons at risk for AD were also found in studies 
The PSEN1 C410Y mutation and memory 
  57 
with functional magnetic resonance imaging (fMRI). Bookheimer et al. (2000) and Bondi et 
al. (2005) found greater magnitude and extent of brain activation in healthy elderly carriers of 
APOE4 during memory-activation tasks in regions affected by AD, including the 
hippocampal, temporal, parietal, and prefrontal regions. The authors argue that such increased 
brain activity may effectively serve a compensatory role, wherein subjects use additional 
cognitive resources to bring memory-related performance to a normal level. However, APOE4 
carriers exhibited already lower performance scores on one of the four delayed recall tests 
than did carriers of the APOE3 allele at the initial neuropsychological testing (both groups 
still fell into the normal range for this age group) and developed memory decline after two 
years. We believe that functional changes in memory-associated brain structures should occur 
far earlier than only two years before clinical onset. This hypothesis is supported by two 
longitudinal studies which document the cognitive profiles of subjects who later developed 
AD over a period of 6 years before clinical onset (Backman et al., 2001; Fox et al., 1998). 
Both studies showed significantly lower scores of verbal episodic memory in individuals who 
manifested clinically within 6 years compared to subjects who remained healthy. These 
findings imply that cognitive decline can precede the clinical phase as long as 6 years. 
However, a recent study failed to show cognitive decline in young PSEN1 mutation carriers 
that were neuropsychologically assessed at least six years prior to clinical onset (Ringman et 
al., 2005). 
It is unknown yet whether cognitively healthy young individuals bearing causative 
mutations on the PSEN1 gene do exhibit abnormal brain activity under cognitive challenge 
and abnormal structural changes 25 years prior to the clinical onset of AD. According to the 
progression of neuropathological deposits, the hippocampus and surrounding structures 
(entorhinal and perirhinal cortices) may exhibit reduced volumes before the clinical 
manifestation of AD (Fox et al., 1996b; Fox et al., 1996a; Kaye et al., 1997; Reiman et al., 
1998). It was found in middle-aged and elderly individuals that genetic mutations do 
influence the degree and regional pattern of atrophy (Gregory et al., 2005). The majority of 
cases had greater medial temporal atrophy than cases with sporadic disease, suggesting that 
abnormalities affecting Aß metabolism selectively increased hippocampal degeneration. 
However, to our knowledge there are no reports in the literature about morphological changes 
in young PSEN1 mutation carriers. Because the genetic defect in FAD is present since birth it 
is conceivable that early neuropathological deposits might induce subtle changes on 
neurophysiologic function and brain metabolism decades before the clinical onset of the 
disease. 
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Here we combined genetics, neuroimaging, and quantitative neuropsychological methods to 
establish the earliest detectable changes in cognition, brain structure and memory-related 
activation levels in carriers of the PSEN1 mutation (C410Y). The mutation carriers and their 
relatives, who do not carry the pathogenic genes, as well as a group of control subjects from 
healthy families were examined with fMRI while they were performing hippocampus-
sensitive episodic memory tasks and hippocampus independent working memory and 
attentional tasks. According to the ‘compensatory hypothesis’ (Bondi et al., 2005; 
Bookheimer et al., 2000) we hypothesized that young carriers of PSEN1 mutations do exhibit 
enhanced brain activity patterns during hippocampus-specific memory tasks at 25 years prior 
to the clinical manifestation of AD, while retaining normal cognitive performance and normal 
brain volumes.  
 
 
Materials and Methods 
 
Subjects 
We examined five nondemented members of a family with FAD: three young (~20 years) and 
two middle-aged (~45 years) individuals. Of the five individuals a young man of 20 years and 
a middle-aged female of 45 years carried the C410Y mutation on the PSEN1 gene. We also 
describe neuropsychology data of two index patients of the family that were clinically 
followed up at our ward. For anonymity reasons the family pedigree and any familial degrees 
of relationship are not reported in this article. As for further reading, the nondemented family 
members are denoted with a Y or an M determining their age group (young or middle-aged). 
The index patients are denoted with an I. In case that they are PSEN1 mutation carriers, the 
abbreviation of the mutation is indicated. The control group consisted of 21 young and 
healthy subjects. They were matched according to the young mutation carrier’s age, years of 
education and APOE genotype (see Table 1 for demographics of the family members and the 
control group). All subjects, except for the index patients, did not suffer from current 
psychiatric or neurological problems and denied to take drugs or medication. Their anatomical 
T1-weighted MRI scans showed normal brain structures as rated by a neurologist (J.S.). All 
subjects gave written informed consent to participate in the study after the nature and possible 
consequences of the study had been explained. The experiments were approved by the ethics 
committee of the Kanton Zurich. 
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Genetic analyses 
Genomic DNA was extracted from whole blood. Mutation screening was performed by direct 
sequencing of both strands of PCR-amplified coding exons of PSEN1 (exon 2-12), PSEN2 
(exon 3-12), exons 16 and 17 of APP, and the single coding exon of PRNP in one index 
patient. In all other members of the family only the mutation site was verified by sequencing 
the exon. In brief, amplification was done by a universal “touch down” protocol, using 
primers as described earlier (available on request) (Finckh et al. 1998). Purified PCR – 
products were sequenced by cycle sequencing, using fluorescent dye dideoxy terminators 
(ABI PRISM® BigDye™ Terminators v 3.0 Cycle Sequencing Kit) and analysis was 
performed on a (ABI PRISM® 310 Genetic Analyzer). APOE genotypes were assessed using 
the LightCyclerTM instrument (Roche Diagnostics Corporation) (Bernard et al. 1999). 
 
Experimental procedure 
All subjects, except the indexpatients, underwent two fMRI experiments, one on episodic 
memory and the other one on working memory (please see Figure 1 of the APOE study for an 
illustration of the study design). Trials were blocked in each fMRI experiment. Subjects 
practiced all fMRI tasks prior to scanning. The same stimuli were used for all subjects to 
reduce inter-subject variance caused by stimulus-generated effects. Responses were collected 
with a response box that subjects held in their dominant hand. 
fMRI Experiment on episodic memory – Encoding. We presented 16 face-profession pairs for 
associative learning, 16 faces for single face learning and 24 head contours without 
physiognomy in the visual baseline condition. The face-profession pairs and the single faces 
were learned over three consecutive learning runs (three separate fMRI time series). The 
instruction for associative learning of the face-profession pairs was to imagine the presented 
person acting in a scene of the written profession. Subjects answered by button press whether 
they found it easy or hard to imagine a scene. The imagination of a scene automatically leads 
to the establishment of semantic person-occupation associations and activates the 
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hippocampal formation (Degonda et al., 2005). Importantly, subjects were requested to 
imagine the same scene for a given face-profession pair during runs 2 and 3 as during run 1. 
The instruction for the learning of single faces was to decide whether a face was pleasant or 
unpleasant. This task yields a semantic encoding of faces. The visual baseline task was to 
decide whether the area of the left or right ear was larger. The sequence of conditions within 
the fMRI time-series was counterbalanced across subjects. Each learning condition consisted 
of four blocks. A block contained four trials of 6 s each. The baseline condition consisted also 
of four blocks. Here, a block contained six trials of 4 s each. Consequently, each task block 
took 24 s. An instruction slide announced each task block. 
fMRI Experiment on episodic memory – Retrieval. We applied a single fMRI time-series for 
the retrieval of the previously learned face-profession associations and faces. This time-series 
included an associative retrieval condition, a face recognition condition, a new faces 
(distracter faces) detection condition and the same visual baseline condition that was used for 
the encoding time-series. For the retrieval of the associations, the previously presented faces 
were shown again (without the professions) as retrieval cues with the instruction to recall each 
person’s occupation and to indicate the superordinate professional category by button press: 
academic or workman. For face recognition/new face detection, old (studied) and new faces 
were presented with the instruction to indicate by button press whether a face was fully 
recollected, appeared just familiar or was completely new (Tulving, 1985). The sequence of 
conditions within the fMRI time-series was counterbalanced across subjects. All conditions, 
except for the visual baseline condition (see above), consisted of four blocks, each block 
including four trials of 6 s each. All task blocks took 24 s and were announced by an 
instruction slide.  
fMRI Experiment on working memory. The experiment included one fMRI time-series with a 
2-back task for the assessment of working memory and a baseline task (‘x-target’) for the 
assessment of concentration. The 2-back task required subjects to respond to a letter repeat 
with one intervening letter (e.g. S – f – s – g). The ‘x-target’ task required subjects to respond 
to the occurrence of the letter ‘x’. 
Each task was given in five blocks of 26 s each. Blocks were announced by an instruction 
slide. Stimuli were 50 upper- or lowercase letters typed in black on a white background. 
Thirteen upper- or lowercase letters were presented per block for the duration of 2 s each.  
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Data acquisition 
MR measurements were performed on a 3T Philips Intera whole body MR scanner equipped 
with an eight-channel Philips SENSE head coil. Functional data were obtained from 32 
transverse slices parallel to the AC-PC plane covering the whole brain with a measured spatial 
resolution of 2.8 x 2.8 x 4 mm3 (acquisition matrix 80 x 80) and a reconstructed resolution of 
1.7 x 1.7 x 4 mm3. Data were acquired using a SENSE-sshEPI (Schmidt et al., 2005) sequence 
with an acceleration factor of R = 2.0. Other scan parameters were TE = 35 ms, TR = 3000 
ms, θ = 82°. A standard 3D T1-weighted scan was obtained for anatomical reference with a 
measured spatial resolution of 1 x 1 x 1.5 mm3 (acquisition matrix 224 x 224) and a 
reconstructed resolution of 0.9 x 0.9 x 0.8 mm3, TE = 2.3 ms, TR = 20 ms, θ = 20°. A 2D T1-
weighted inversion-recovery anatomical scan, oriented perpendicularly to the long axis of the 
hippocampus, was obtained for hippocampal and parahippocampal volumetry over 33-39 
slices with a measured spatial resolution of 0.5 x 0.6 x 1.5 mm3 (acquisition matrix 400 x 320) 
and a reconstructed spatial resolution of 0.4 x 0.4 x 1.5 mm3, TE = 15 ms, TR = 4200 ms, θ = 
20°, IR delay 400 ms, no interslice gaps. 
 
Analysis of functional MRI data 
Image pre- and postprocessing and the statistical analyses were performed with SPM2 
(http://www.fil.ion.ucl.ac.uk/spm). Standard preprocessing procedures were applied in two 
ways: once with realignment, spatial normalization and spatial smoothing (8 mm) (Friston et 
al., 1995a) for a random effects analysis (RFX), and once with realignment and smoothing 
(4mm) - no spatial normalization - for an additional region-of-interest (ROI) analysis of each 
subject. On the single subject level, data were analyzed according to the fixed effects model 
(SPM2). The six head movement parameters were included in the model as confounding 
factors. Data were high-pass filtered with a specific filter-value for each fMRI time-series. 
This value was determined according to ‘2*SOA*TR’. Contrasts for each subject were 
calculated by subtracting the baseline condition from the experimental condition. On the 
second level, within-subject contrasts were entered into a RFX analysis (Two sample T-tests, 
SPM2) which accounts for variance between subjects (Friston et al., 1995b). It is possible in 
SPM to compare a single subject with a group of controls. The two-sample t-test implemented 
with that option in SPM takes the control groups’ variance as an estimate for the single 
subject. Thresholds were set at a p < 0.001 level, uncorrected for multiple comparisons, with 
an extend threshold of 15 voxels; exceptions (p < 0.005, 3 voxels extend) were made for the 
region of interest, i.e., the hippocampus, and are indicated where applicable.  
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For the purpose of a more accurate statistical analysis in the hippocampus a Region-of-interest 
(ROI) analysis was performed using the MarsBar toolbox in SPM2 (Brett et al., 2002). Both 
hippocampi were manually delineated on the 3D-T1-weighted structural MRI images of each 
subject. Mean contrast values for each subject and condition were extracted for each ROI. The 
mean contrast values of each family member were then separately compared to the 7th (P7) 
and 93rd (P93) percentile of the control group’s mean contrast values. The P7 and the P93 
correspond to +/- 1.5 SDs. 
 
Analysis of anatomical MRI data 
Based on the 3D-T1-weighted structural MRI images which covered the whole brain, volumes 
of the total gray and white matter were computed with SPM2. Images were first normalized 
into the MNI T1 template using a standard bounding box and then segmented into gray 
matter, white matter and cerebrospinal fluid. Standardized gray and white matter volumes 
were then multiplied by the determinant of the linear transformation matrix to obtain gray and 
white matter volumes in cm3. Based on the 2D-T1-weighted high resolution structural MRI 
images, two independent raters (A.B. and H.M.) manually delineated the hippocampal 
formation (Henke et al., 1999a) (CA regions, dentate gyrus and subiculum, excluding the 
fimbria) and the parahippocampal gyrus using the software Pmod (http://www.pmod.com.). 
Cerebrospinal fluid was carefully excluded which resulted in conservative volume estimates. 
Raters relied on descriptions of anatomical landmarks and subdivisions of the MTL as 
described by Insausti et al. (1998) and Duvernoy (1998). Inter-rater reliabilities ranged 
between r = 0.8 and 0.98. Each family member’s volumes were compared to the P7 and P93 
of the control group’s volumes. The male mutation carrier was separately compared to a 
control group consisting of 9 males (age mean 21.1, SD 1.7), while the four female family 
members were compared to a female control group (n = 13; age mean 22, SD 1.8). 
 
Neuropsychology 
The index patients were examined with standardized dementia screening tests like the Mini 
Mental State Examination (MMSE) (Folstein et al., 1975), the test battery of the Consortium 
to Establish a Registry for Alzheimer’s Disease (CERAD) (Morris et al., 1989) and the 
Alzheimer’s Disease Assessment Scale - Cognitive Subscale (ADAS-cog) (Rosen et al., 
1984). Additional tests were applied for the measurement of executive functions, language 
abilities, spatial cognition, semantic memory, perception, and practical acting. 
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In the nondemented family members, memory functions were assessed with the Wechsler 
Memory Scale Revised (WMS-R) (Härting et al., 2000) in German. Intelligence was 
measured with the Hamburg Wechsler Intelligence Test (HAWIE) (Tewes, 1991). Spatial 
cognition was tested with the Luria Mental Rotation Test (Christensen, 1979). Executive 
functions were assessed with a verbal (S-Words) and a nonverbal (5-Point) fluency task 
(Regard et al., 1982), with the Kramer Card Sorting Test (Kramer, 1970), which measures 
concept finding and shifting abilities, and with the Stroop Test (Stroop, 1935), which 
measures the suppression of interference. The two middle-aged family members were 
additionally examined with the MMSE and the CERAD battery. Test scores of each family 
member were compared to the P7 and P93 of the control group’s scores. Furthermore, the 
subjects’ scores in the WMS-R and HAWIE subtests were compared to an age-matched 
normative population. 
 
Results 
 
Neuropsychology 
Follow up - indexpatients 
The clinical follow up of the index patients started in the years 2000/2001 at our ward, and is 
still running.  
Patient I1 C410Y had his first visit at our outpatient ward at the age of 51. He was 
disoriented to time and place and presented with pronounced deficits (> 2 SDs) in the 
learning, retrieval and recognition of verbal and figural material. We also found impairments 
in executive functions and semantic memory (factual knowledge). In the next two years the 
patient was seen another three times for neuropsychological assessment. The episodic 
memory deficits progressed until almost complete memory loss of recent events. Also, 
orientation and executive functions got worse and the patient started to show signs of apraxia 
and deficits in working memory and language.  
Patient I2 C410Y first presented at our outpatient ward at the age of 50 years. He was 
examined five times during a period of 4 years. At the initial visit he presented with a 
selective impairment of retrieval of previously learned verbal and figural material (> 2 SDs). 
Learning and recognition of this verbal and figural material were slightly reduced. Executive 
functions were slightly reduced as well. Memory deterioration then progressed during the next 
four years until he almost completely lost memory for recent events. The patient exhibited 
apraxia and more pronounced deficits in executive functions, working memory, semantic 
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memory, spatial thinking and visuoconstruction. However, language abilities remained 
preserved.  
 
Young subjects 
The young mutation carrier Y1 C410Y fell below the control groups 7th percentile in the 
indices for visual memory and delayed memory of the WMS-R (Fig. 1). The subtests that 
mainly contributed towards the low ranks in both indices were the visual paired associations 
(VPA) learning and recall tasks. This hints towards a selective impairment of visual memory 
capacity in the young mutation carrier. When compared to a normative age-matched 
population, performance scores in the visual paired associations tasks were more than two 
SDs below the population mean (Score VPA1; Y1 C410Y: 10, Controls: mean: 14.10, SD: 
3.14, score VPA2; Y1 C410Y: 4, controls mean: 5.48, SD: 0.78). According to (Petersen et al., 
2001) these deficits in visual memory would be clinically diagnosed as a mild cognitive 
impairment (MCI), a transitional state between the cognitive changes associated with normal 
aging and with AD. In other words, persons with MCI experience memory loss to a greater 
extent than one would expect for their age.  The selectivity of the visual memory impairment 
is underscored by the fact that in all other neuropsychological tests subject Y1 C410Y 
performed within the P7/P93 range. Furthermore, this subject impressed with a high total 
intelligence quotient, that nearly reached the control group’s P93 (Fig. 1). For an overview of 
the neuropsychology scores of all five family members please see supplementary table S1.  
Subject’s Y2 scores in the memory and IQ indices and in all the other 
neuropsychological tests were located within or above the P7/P93 range of the control group’s 
performance (Fig. 1). This subject can therefore be regarded as a cognitively healthy young 
study participant. 
Subject Y3 showed deficits on a broad range of cognitive functions. All memory 
indices, the total IQ score, the verbal IQ score, and verbal fluency ranged below the 7th 
percentile of the control group (Fig. 1). This reduced general cognition is probably standing 
for a naturally low ability which is unrelated to FAD. 
 
Middle-aged subjects 
The 45-years old mutation carrier M1 C410Y  fell off the control groups 7th percentile in all 
memory indices of the WMS-R but retained total IQ and all further performance scores within 
the P7/P93 range (Fig. 1). The performance scores in the memory subtests were below two 
SDs of a normative age-matched control group’s mean (Table S1). This subject presents with 
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progressed selective memory impairments and can therefore be clinically diagnosed with MCI 
(Petersen et al., 2001), which eventually will develop into an Alzheimer’s dementia in the 
near future.  
Subject M2 (52 years old) scored below the P7/P93 range only in the total IQ and the 
verbal IQ index (Fig. 1). She can therefore be regarded as a cognitively healthy middle-aged 
study subject with a naturally low cognitive level. 
 
Fig. 1. Neuropsychology data. Shown are the performance scores of the five family members in the indices of 
the Wechsler Memory Scale revised (WMS-R) and the Hamburg Adult Wechsler Intelligence Scale (HAWIE). 
Family members are denoted by a colored symbol (see legend). The grey area reflects the control group’s 
performance between the 7th and the 93rd percentile. IQ, intelligence quotient; MQ, memory quotient. 
 
 
Behavioral results – fMRI memory tasks 
The young subjects performed within the P7/P93 range of the control group’s performance 
during the associative and the single face learning/retrieval tasks and during the working 
memory and the attentional tasks (Table 2).  
Each and every young subjects’ number of ‘easy’ (to imagine) answers during associative 
learning increased over learning runs, indicating effective learning over runs. Likewise, their 
‘pleasant’ answers increased over runs during single face learning, indicating that repeatedly 
presented faces got more familiar and consequently were judged more pleasant. 
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In contrast to the young family members, both of the two middle-aged subjects decreased the 
number of their ‘easy’ answers over runs during associative learning, with the middle-aged 
mutation carrier M1 C410Y  having the smallest amount of ‘easy’ answers of all familiy 
members over the three runs (Σ ‘easy’ all runs; Y1 C410Y : 32, Y2: 31, Y3: 28, E1 C410Y: 25,  
M2: 31, see Table 2). However, the number of ‘pleasant’ answers during single face learning 
increased over runs for each of the two middle-aged family members, and ranged within 
P7/P93 of the control group. This indicates that imagining a scene during associative learning 
was more difficult for the middle-aged subjects than learning a single face. Interestingly, the 
middle-aged subjects fell below the control group’s P7/93 range only for the single face 
retrieval task and for the novel face detection task, but not for the associative retrieval task. 
The middle-aged mutation carrier M1 C410Y  achieved the smallest amount of ‘remember’ 
and ‘know’ answers during single face retrieval as compared to the control group and to the 
other family members (Σ ‘remember’ & ‘know’; Y1 C410Y : 15, Y2: 14, Y3: 12, E1 C410Y : 3, 
M2: 8, see Table 2). The other middle-aged subject M2 had also only a few ‘remember’ 
answers, but in her case, she compensated her low retrieval performance from episodic 
memory with a larger amount of ‘know’ (semantic memory) answers. Both middle-aged 
subjects unreliably recognized new faces, falling clearly below the control group’s P7/P93 
range. Subject M2 even recognized only one new face out of 16. This bad performance was 
mainly due to a lot of false positive answers during the novel face detection task. Subject M2 
also performed badly in the 2-back task, again because of a large amount of false positives. 
This might indicate an attentional problem of this subject during the working memory and 
single faces tasks. However, the decreased performance of subject E1 C410Y appears only in 
episodic memory tasks, and therefore reliably mirrors her deficits in the neuropsychological 
examination. 
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Functional imaging results 
Young subjects 
As compared to controls, the young mutation carrier Y1 C410Y showed enhanced brain 
activity distributed over many brain regions during learning and retrieval, novelty detection, 
and during the working memory experiment (see Supplementary Table S2 for locations of 
brain activity). Importantly, reversing the contrasts (i.e. comparing the control group with 
subject Y1 C410Y)  yielded some brain areas (left superior frontal gyrus, left cingulate and 
bilateral superior temporal gyrus) with enhanced activity for the working memory task but not 
for learning/retrieval tasks nor for novelty detection. The most prominent activity 
enhancement of subject Y1 C410Y versus the control group was found in a left-lateralized 
transcortical network including the hippocampus during associative learning (Table 3) and in 
a left fronto-temporo-parietal network during associative retrieval (Table 4).  
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A ROI analysis confirmed that the young mutation carrier’s hippocampal activity during 
associative learning ranged above the control group’s 93rd percentile of the control group’s 
activity. This activity enhancement could be attributed to the middle portion of the left 
hippocampus (Figure 2). In all the other contrasts, hippocampal activity ranged within the 
control group’s P7/P93 (Figures 2 & 3). 
 
 
Fig. 2. ROI analysis data - learning tasks. Shown are the family members’ contrast estimates in the left and right 
hippocampal subdivisions (i.e. anterior, middle, posterior) during associative and single face learning. Family 
members are denoted by a colored symbol (see legend).The grey area reflects the control group’s contrast 
estimates between the 7th and the 93rd percentile.  
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Fig. 3. ROI analysis data - retrieval and new face detection tasks. Shown are the family members’ contrast 
estimates in the left and right hippocampal subdivisions (i.e. anterior, middle, posterior) during associative and 
single face retrieval, and new face detection. Family members are denoted by a colored symbol (see legend).The 
grey area reflects the control group’s contrast estimates between the 7th and the 93rd percentile.  
 
To gain further evidence that the enhanced activity in subject Y1 C410Y was related to 
the PSEN1 gene mutation, we randomly selected 6 controls subjects and compared each of 
them with the remaining 20 subjects of the control group. As shown in Figure 4 only subject 
R2 exhibited enhanced activity compared to the controls during associative learning (R2: right 
superior frontal gyrus, left superior occipital gyrus, left basal ganglia and cerebellum; R5: 
artefactual activation of white matter). A similar outcome is shown for the associative 
retrieval contrast where again only two subjects, R2 and R4, exhibited two spots of enhanced 
activity as did controls (R2: left middle frontal gyrus, left cerebellum; R4: left middle and 
superior frontal gyrus). However, the activity increases in these control subjects were of a 
smaller cluster size and only present in very few brain regions as compared to the young 
mutation carrier. 
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Fig. 4. Brain activity enhancement in the young mutation carrier during associative learning and retrieval. Upper 
panel: Activity differences between the young mutation carrier and the control group during associative learning 
and retrieval are depicted on a glass brain. Lower panel: Six randomly selected control subjects were compared 
to the control group. Activity differences are depicted on a glass brain. Note that subject Y1 C410Y reliably 
shows enhanced activity in various brain areas as compared to controls during associative learning and retrieval 
while the six randomly selected controls subjects show only marginal differences or none at all.  
 
Subject Y2 also showed a few neocortical brain areas with enhanced brain activity 
during learning and retrieval, novelty detection and during the working memory task as 
compared to the control group (Supplementary Table S3). Reversing the contrasts yielded 
some regions of stronger activity in the control group as well, but only during the associative 
retrieval task (Table 4) and the new face detection task (Supplementary Table S3).  
The ROI analysis revealed that subject’s Y2 left posterior hippocampal activity ranged 
below the 7th percentile of the control group’s activity during associative retrieval, while 
hippocampal activity in the left anterior hippocampus was above the 93rd percentile during 
single face retrieval. 
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Enhanced brain activity during learning/retrieval, novelty detection and working memory was 
also found in subject Y3 as compared to the control group. Again, similarly to subject Y2, 
enhanced brain activity occurred only in a few neocortical brain areas (Supplementary Table 
S4). By reversing the contrasts we could see that the control group exhibited enhanced brain 
activity in various areas, predominantly in medial temporal lobe structures (MTL) during 
associative retrieval (Table 4), face recognition and new face detection (Supplementary Table 
S4). Differences in activity of MTL structures were replicated in the ROI analysis. Here 
subject Y3 fell below P7 in the left posterior hippocampus during associative retrieval and in 
the left anterior, middle and posterior hippocampus and the right anterior hippocampus during 
single face retrieval. In the new face detection task hippocampal activity ranged near the 
control’s 7th percentile (Figures 2 & 3). 
 
Middle-aged subjects 
The middle-aged mutation carrier E1 C410Y showed almost no brain areas with enhanced 
activity compared to controls, except in the right middle frontal gyrus during single face 
learning, the right orbital gyrus during associative retrieval and some fronto-parietal areas 
during the working memory task (Supplementary Table S5). Reversing the contrasts revealed 
that the control groups’ brain activity was stronger in MTL structures and a memory-related 
neocortical network as compared to M1 C410Y in all contrasts, except during working 
memory. Again, these differences of activity strength between the family member and 
controls became mainly apparent during associative learning and retrieval (Tables 3 & 4).  
The lower activity level of the middle-aged mutation carrier was also apparent in the 
ROI analysis. Here, activity in various hippocampal subdivisions strikingly fell below the 
control group’s 7th percentile during single face and associative learning/retrieval and during 
novelty detection (Figures 2 & 3). 
Subject M2 showed enhanced brain activity in a few areas during associative learning 
and working memory, as compared to the control group (Supplementary Table S6). Reversing 
the contrasts showed enhanced activity of the control group in the hippocampus and memory-
related neocortical areas mainly during associative learning and retrieval (Tables 3 & 4, 
Supplementary Table S6) but also during face recognition and novelty detection. 
The ROI analysis revealed that activity in the left posterior hippocampus fell off P7 
during learning/retrieval and during novelty detection in subject M2 (Figures 2 & 3).  
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We analyzed repetition effects in each family member during learning by contrasting the first 
with the third learning run. This analysis did not yield a reliable effect of the PSEN1 mutation 
on brain activity underlying repeated learning. Therefore this data is not shown. 
Taken together, these results show that the young mutation carrier exhibited enhanced 
activity in memory-related neural structures compared to his young family relatives and 
compared to the control group. This enhancement of brain activity appears in all contrasts, 
though predominantly during associative learning and retrieval, a measure of episodic 
memory (Table 4). This pattern of activation stands in clear contrast to the other two young 
family members in whome only a few brain areas of enhanced activity were detected. 
Furthermore both young mutation noncarriers also exhibited areas of decreased activity, while  
subject Y1 C410Y almost exclusively exhibited areas of enhanced activity.  
Nearly the opposite pattern was seen in the middle-aged subjects. Here, the mutation 
carrier exhibited almost only areas of decreased memory-related activity during learning and 
retrieval. In comparison the non-carrier showed only few areas of decreased activity, but also 
some areas of enhanced activity. 
 
 
Structural imaging results 
Manual volume measurements of both hippocampi and both parahippocampal gyri revealed 
comparable volumes between the family subjects and the respective control groups 
(Supplementary Table S7). Automated whole brain grey and white matter segmentation 
showed less (below the control group’s 7th percentile) grey matter in subjects Y1 C410Y and 
Y3. However, this differences in grey matter volumes are not explainable by grey matter loss 
but rather by small head sizes of these two subjects, as was confirmed by their head 
transformation matrices (data not shown) resulting after normalization in SPM2. 
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Discussion 
In this study we examined five nondemented members of a family with autosomal dominant 
FAD to determine preclinical signs of the disease. A young man (20 years) and a middle-aged 
woman (45 years) carried the C410Y mutation in the PSEN1 gene. The five subjects 
underwent fMRI while performing episodic and working memory tasks. Their brain volumes 
were measured with structural imaging and cognitive status was assessed by applying 
quantitative neuropsychological methods.  
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We found that in the young PSEN1 mutation carrier neuropsychological performance 
scores were selectively decreased (> 2 SDs) in tasks measuring visual and delayed memory. 
Such a selective impairment in episodic memory is clinically diagnosed as MCI (Petersen et 
al., 2001). Although age of onset is around 48 years in this family, memory loss is already 
detectable 28 years prior to AD diagnosis in this individual case. Because this subject 
performed very well in all other neuropsychological tests and impressed with high 
intelligence, we think that the selective drop in visual episodic memory must be related to 
neuronal dysfunction in the MTL. Selective memory loss was also detected in the middle-
aged mutation carrier at age 45. In comparison to the young mutation carrier, her deficits were 
further progressed and affected both verbal and visual memory. In contrast, one of the young 
mutation noncarriers showed unspecific broad cognitive deficits that are attributable with high 
probability to her inherent low intelligence and low general cognitive capacity. Therefore, we 
think that the selective memory impairments in the young and the middle-aged mutation 
carrier are specifically related to the PSEN1 C410Y mutation. In a longitudinal study Fox et 
al. (1998) found earliest clinical and neuropsychological features of FAD only 4-5 years 
before individuals at genetic risk for FAD fulfilled criteria for probable AD. Likewise, a 
recent study failed to discover memory loss decades before the onset of FAD (Ringman et al., 
2005). However, frontal-executive dysfunctions have been found in young subjects at risk for 
frontotemporal dementia due to a pathogenic mutation in the tau gene (FTD-17). These 
dysfunctions have been attributed to a neurodevelopmental component (Geschwind et al., 
2001). The early impairment of episodic memory in our young mutation carrier likely reflects 
an early dysfunction of MTL structures. According to the neuropathological course of AD 
(Braak and Braak, 1996; Delacourte et al., 1999; Price et al., 1991) our data suggest that this 
subject might be suffering from early neuropathological deposits in MTL structures, 
impacting negatively on episodic memory already some 30 years before fully pronounced 
AD. The genetic defect in FAD is present since birth, but it is unclear at what point it starts to 
show effects at the cellular level. In support of early neuropathological changes are studies in 
Down’s syndrome, where deposition of Aß 1-42 has been observed as early as the third 
decade (Stoltzner et al., 2000; Teller et al., 1996). 
The behavioral results in the fMRI experiments did not differentiate the young 
mutation carrier from the control group or from the young noncarriers of the family. 
According to the selective visual and delayed memory deficits of the young mutation carrier 
in the neuropsychological tests one would expect shortcomings during the fMRI retrieval 
tasks. That was not the case and the mismatch in memory performance between the 
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neuropsychological tasks and the fMRI experiments might likely be explained through the 
repetitive nature of our learning tasks, and the learning instruction which required the subjects 
to recall their imagined scenes in the subsequent runs. Therefore, repetitive learning and the 
application of a given learning strategy allowed for a deeper encoding of the material, hence 
increasing memory performance at retrieval. This notion is underscored by the results during 
repeated associative and single face learning. Here, the number of easy [to imagine a scene] 
answers increased from run1 to run3 in each and every young family member reflecting a 
learning process that got facilitated over runs. The same was true for repeated single face 
learning, where pleasant answers increased over runs, reflecting that faces got more and more 
familiar, consequently judged more pleasant (mere exposure effect).  
Unexpectedly as well, the middle-aged mutation carrier - although diagnosed with 
MCI according to her neuropsychological outcome - reached a normal performance during 
associative retrieval. Her number of easy [to imagine a scene] answers decreased from run1 to 
run3 during associative learning, reflecting that the associative learning task remained 
cognitively demanding to her in each run. In contrast, retrieval of single faces alone was far 
below the control group’s mean (> 2 SDs) for both ‘remember minus false remember’ and 
‘know minus false know’ answers, while the latter was mainly due to a high rate of false 
positives in the new face detection task. These differences in performance between associative 
retrieval – which is clearly more difficult – and single face retrieval can best be explained by 
the nature of the tasks and the depth of processing of the presented stimuli at the level of 
encoding. The repeated imagination of a scene during associative learning, along with the 
recall and re-encoding processes of the very same scenes in run2 and run3, have allowed for a 
much deeper encoding of the associations as compared to the single faces alone, which only 
had to be rated according to their pleasantness. As reflected in the decreased easy [to imagine 
a scene] answers over runs, learning of associations was a challenging task for the middle-
aged mutation carrier. She therefore might have put more effort into learning the associations 
than single faces, hence boosting her associative retrieval performance. 
The fMRI results showed that both mutation carriers exhibited significantly altered 
patterns of memory-related brain activity compared to the control group and the family 
members without the mutation. The young mutation carrier consistently exhibited enhanced 
brain activity in nearly every task. This enhancement was specifically pronounced during 
associative learning and retrieval, and was present in the hippocampus and many memory-
related neocortical areas. The increase in brain activity was not paralleled by significant 
performance changes between this subject and the controls, neither by differences in brain 
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volumes. These results are consistent with a compensatory hypothesis where the young 
mutation carrier appears to require additional cognitive effort to achieve the same level of 
performance as the control group. It has been demonstrated for a variety of cognitive tasks 
that increasing task demands are associated with the spatial extend and the magnitude of brain 
activity in the task-specialized neural network (Bookheimer et al., 2000; Carpenter et al., 
1999; Just et al., 1996). These findings generally indicate that the amount of neural activity 
that a given task engenders is dependent on the computational demand that the task imposes. 
Interestingly, larger task-related activity enhancements in the MTL and neocortex have been 
found in elderly nondemented AD-risk allele (APOE4) carriers (Bondi et al., 2005; 
Bookheimer et al., 2000) and in cases with selective memory impairment (MCI) (Dickerson et 
al., 2004; Rosano et al., 2005). This activity enhancement was predictive for further cognitive 
decline (Bookheimer et al., 2000; Dickerson et al., 2004). The most likely explanation for the 
increased activation in the MTL and neocortical regions is a compensatory response to 
accumulating AD pathology (Becker et al., 1996; Bookheimer et al., 2000; Grady et al., 
2003). This line of argumentation even holds stronger with regard to the brain activity 
enhancements found in our young PSEN1 mutation carrier. Neuropathological changes in this 
man might have taken place since birth and consequently could have had the potential to 
impact on cognition and normal neuronal functioning already three decades before the clinical 
onset of AD. We are aware that multiple nonneural factors may confound the interpretation of 
changes in the hemodynamic fMRI response during activation, such as AD-specific 
alterations in vascular physiology (Johnson et al., 2000; Mueggler et al., 2002), age- and 
disease-related changes in neurovascular coupling (Buckner et al., 2000; D'Esposito et al., 
2003), and resting hypoperfusion and metabolism in MCI and AD (De Santi et al., 2001; El 
Fakhri et al., 2003; Johnson et al., 1998). However, because of the young age of the mutation 
carrier, we don’t think that these factors are responsible for the amplified fMRI signal. 
The middle-aged PSEN1 mutation carrier exhibited almost exclusively decreased 
activity in the MTL and memory-related areas in all episodic memory tasks. Her low face 
recognition performance is the most likely cause for the decreased brain activity in that task. 
It has been shown in several studies, that retrieval success is associated with enhanced 
activity, while retrieval failure is associated with decreased activity in memory-related brain 
structures (Daselaar et al., 2003; Maril et al., 2005; McDermott et al., 2000; Meltzer and 
Constable, 2005). Furthermore, early stage AD patients with cognitive impairments show 
decreased task-induced brain activity in brain areas mediating the cognitive demands of the 
task (Buckner et al., 2000; Kato et al., 2001; Small et al., 1999). Decreased activity in the 
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associative learning and retrieval tasks can not be explained by a lower memory performance, 
because she achieved comparable levels to the control group in the associative retrieval task. 
However, according to her selective episodic memory deficits in the neuropsychological 
examination this subject can be classified as a MCI patient. In opposition to our findings are 
studies with fMRI in MCI patients that found compensatory task-induced brain activity which 
was predictive for later cognitive decline (Dickerson et al., 2004; Rosano et al., 2005). An 
explanation for this mismatch could be a further progressed accumulation of AD pathology in 
the middle-aged PSEN1 mutation carrier as compared to sporadic forms of AD. FAD-cases 
suffer from a faster disease progression and are affected by more abundant neuropathological 
deposits (Gomez-Isla et al., 1997; Lippa et al., 2000; Sakamoto et al., 2002). Therefore it is 
likely that the decreased memory-related brain activity in our middle-aged mutation carrier is 
related to neural dysfunction induced by AD-pathology that progressed beyond MTL 
structures. The aggressive nature of AD pathology in FAD might be responsible for a much 
more extensive degree of neural dysfunction than in sporadic forms of AD, hence impeding a 
recruitment of still functioning neural reserves a few years before diagnosis of the disease. 
There are several limitations to our study. Since the frequency of FAD cases is very 
low, we just managed to examine one family with FAD. Only one young mutation carrier of 
this family agreed to take part in the study. Therefore the conclusions can not be extended to 
the majority of probable AD cases and must be considered tentative. However, this is the first 
study to detect preclinical signs of AD on the behavioural and neural level decades before the 
onset of the disease. To further validate this finding, a follow up of the examined family 
would be a great gain. Also, additional examinations with imaging techniques measuring 
metabolic changes would have given additional and valuable insight into what processes are 
under way some 25 years before the clinical onset of the disease. 
Taken together, our results suggest, that cognitive and neural dysfunction is detectable 
three decades before clinical onset of AD in PSEN1 C410Y mutation carriers. It is highly 
likely that these changes are related to accumulating AD pathology. Although past studies 
failed to detect early preclinical signs in other PSEN1 missense mutations, this does not 
impose that our findings are related to the PSEN1 C410Y mutation only. We propose that in 
the future fMRI might be a valuable tool for the early detection of AD. In conjunction with 
other imaging methods and neuropsychological assessment it will allow us to gain insight into 
the staging of the disease and into the progression from healthy status to the clinical onset, 
possibly even in the more frequent sporadic forms. 
 
The PSEN1 C410Y mutation and memory 
  79 
Reference List 
 
Alzheimer's Disease Collaborative Group (1995) The structure of the presenilin 1 (S182) gene 
and identification of six novel mutations in early onset AD families. Alzheimer's disease 
Collaborative Group. Nat Genet 11:219-222. 
Backman L, Small BJ, Fratiglioni L (2001) Stability of the preclinical episodic memory 
deficit in Alzheimer's disease. Brain 124:96-102. 
Becker JT, Mintun MA, Aleva K, Wiseman MB, Nichols T, DeKosky ST (1996) 
Compensatory reallocation of brain resources supporting verbal episodic memory in 
Alzheimer's disease. Neurology 46:692-700. 
Bernard PS, Pritham GH, Wittwer CT. (1999) Color multiplexing hybridization probes using 
the apolipoprotein E locus as a model system for genotyping. Anal Biochem. 273(2):221-8. 
 
Bondi MW, Houston WS, Eyler LT, Brown GG (2005) fMRI evidence of compensatory 
mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 64:501-508. 
Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, 
Small GW (2000) Patterns of brain activation in people at risk for Alzheimer's disease. New 
England Journal of Medicine 343:450-456. 
Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta 
Neurologica Scandinavica 93:3-12. 
Brett M, Anton JL, Valabregue R, Poline JB (2002) Region of interest analysis using an SPM 
toolbox. Presented at the 8th International Conference on Functional Mapping of the Human 
Brain, June 2-6, 2002, Sendai, Japan. 
Buckner RL, Snyder AZ, Sanders AL, Raichle ME, Morris JC (2000) Functional Brain 
Imaging of Young, Nondemented, and Demented Older Adults. J Cogn Neurosci 12:24S-34. 
Carpenter PA, Just MA, Keller TA, Eddy W, Thulborn K (1999) Graded functional activation 
in the visuospatial system with the amount of task demand. J Cogn Neurosci 11:9-24. 
Christensen AL (1979) Luria's neuropsychological investigation manual. Copenhagen: 
Munksgaard. 
Cruts M, van Broeckhoven C. (1998) Presenilin mutations in Alzheimer's disease. Hum Mutat 
11:183-190. 
Czech C, Tremp G, Pradier L (2000) Presenilins and Alzheimer's disease: biological functions 
and pathogenic mechanisms. Prog Neurobiol 60:363-384. 
D'Esposito M, Deouell LY, Gazzaley A (2003) Alterations in the BOLD fMRI signal with 
ageing and disease: a challenge for neuroimaging. Nat Rev Neurosci 4:863-872. 
Daselaar SM, Veltman DJ, Rombouts SARB, Raaijmakers JGW, Jonker C (2003) 
Neuroanatomical correlates of episodic encoding and retrieval in young and elderly subjects. 
Brain 126:43-56. 
The PSEN1 C410Y mutation and memory 
  80 
de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, 
Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier 
J, Reisberg B, Fowler J (2001) Prediction of cognitive decline in normal elderly subjects with 
2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl 
Acad Sci U S A 98:10966-10971. 
De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, 
Boppana M, Daisley K (2001) Hippocampal formation glucose metabolism and volume losses 
in MCI and AD. Neurobiology of Aging 22:529-539. 
Degonda N, Mondadori CR, Bosshardt S, Schmidt CF, Boesiger P, Nitsch RM, Hock C, 
Henke K (2005) Implicit associative learning engages the hippocampus and interacts with 
explicit associative learning. Neuron 46:505-520. 
Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghozali F, Fallet-
Bianco C, Pasquier F, Lebert F, Petit H, Di MC (1999) The biochemical pathway of 
neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52:1158-1165. 
Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, 
Blacker D, Albert MS, Sperling RA (2004) Medial temporal lobe function and structure in 
mild cognitive impairment. Ann Neurol 56:27-35. 
Duvernoy H.M. (1998) The human Hippocampus. Berlin: Springer Verlag. 
El Fakhri G, Kijewski MF, Johnson KA, Syrkin G, Killiany RJ, Becker JA, Zimmerman RE, 
Albert MS (2003) MRI-Guided SPECT Perfusion Measures and Volumetric MRI in 
Prodromal Alzheimer Disease. Arch Neurol 60:1066-1072. 
Finckh U, Muller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, Binetti G, 
Alberici A, Hock C, Nitsch RM, Gal A. (2000) High prevalence of pathogenic mutations in 
patients with early-onset dementia detected by sequence analyses of four different genes. Am 
J Hum Genet. 66(1):110-7.  
 
Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": A practical method for 
grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 
12:189-198. 
Fox NC, Freeborough PA, Rossor MN (1996a) Visualisation and quantification of rates of 
atrophy in Alzheimer's disease. Lancet 348:94-97. 
Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor 
MN (1996b) Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal 
MRI study. Brain 119:2001-2007. 
Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN (1998) Presymptomatic 
cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal 
prospective study. Brain 121 ( Pt 9):1631-1639. 
Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RSJ (1995a) Spatial 
registration and normalization of images. Human Brain Mapping 3:165-189. 
Friston KJ, Holmes AP, Poline JB, Grasby PJ, Williams SCR, Frackowiak RSJ, Turner R 
(1995b) Analysis of Fmri Time-Series Revisited. Neuroimage 2:45-53. 
The PSEN1 C410Y mutation and memory 
  81 
Geschwind DH, Robidoux J, Alarcon M, Miller BL, Wilhelmsen KC, Cummings JL, 
Nasreddine ZS (2001) Dementia and neurodevelopmental predisposition: cognitive 
dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal 
dementia. Ann Neurol 50:741-746. 
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes 
A, Irving N, James L, . (1991) Segregation of a missense mutation in the amyloid precursor 
protein gene with familial Alzheimer's disease. Nature 349:704-706. 
Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, 
McNamara M, Rodes LA, DiBlasi T, Growdon WB, Seubert P, Schenk D, Growdon JH, 
Hyman BT, Tanzi RE (1997b) A novel presenilin-1 mutation: increased beta-amyloid and 
neurofibrillary changes. Ann Neurol 41:809-813. 
Gomez-Isla T, Wasco W, Pettingell WP, Gurubhagavatula S, Schmidt SD, Jondro PD, 
McNamara M, Rodes LA, DiBlasi T, Growdon WB, Seubert P, Schenk D, Growdon JH, 
Hyman BT, Tanzi RE (1997a) A novel presenilin-1 mutation: increased beta-amyloid and 
neurofibrillary changes. Ann Neurol 41:809-813. 
Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE (2003) Evidence from 
Functional Neuroimaging of a Compensatory Prefrontal Network in Alzheimer's Disease. J 
Neurosci 23:986-993. 
Gregory GC, Macdonald V, Schofield PR, Kril JJ, Halliday GM (2005) Differences in 
regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging. 
Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinge K, Kessler J (2000) Wechsler 
Gedächtnis Test-Revidierte Fassung (WMS-R): Deutsche Adaptation der revidierten Fassung 
der Wechsler Memory Scale. Bern, Switzerland: Verlag Hans Huber. 
Henke K, Kroll NEA, Behniea H, Amaral DG, Miller MB, Rafal R, Gazzaniga MS (1999) 
Memory lost and regained following bilateral hippocampal damage. Journal of Cognitive 
Neuroscience 11:682-697. 
Insausti R, Juottonen K, Soininen H, Insausti AM, Partanen K, Vainio P, Laakso MP, 
Pitkanen A (1998) MR volumetric analysis of the human entorhinal, perirhinal, and 
temporopolar cortices. AJNR Am J Neuroradiol 19:659-671. 
Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, Albert MS (1998) 
Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50:1563-1571. 
Johnson SC, Saykin AJ, Baxter LC, Flashman LA, Santulli RB, McAllister TW, Mamourian 
AC (2000) The relationship between fMRI activation and cerebral atrophy: comparison of 
normal aging and alzheimer disease. Neuroimage 11:179-187. 
Just MA, Carpenter PA, Keller TA, Eddy WF, Thulborn KR (1996) Brain activation 
modulated by sentence comprehension. Science 274:114-116. 
Kato T, Knopman D, Liu H (2001) Dissociation of regional activation in mild AD during 
visual encoding: A functional MRI study. Neurology 57:812-816. 
The PSEN1 C410Y mutation and memory 
  82 
Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, Karnos T, Camicioli R, Ball M, 
Oken B, Sexton G (1997) Volume loss of the hippocampus and temporal lobe in healthy 
elderly persons destined to develop dementia. Neurology 48:1297-1304. 
Kramer J (1970) Kurze Anleitung zum Intelligenztest. Solothurn: Antonius Verlag. 
Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro 
PD, Schmidt SD, Wang K, . (1995) Candidate gene for the chromosome 1 familial 
Alzheimer's disease locus. Science 269:973-977. 
Lippa CF, Swearer JM, Kane KJ, Nochlin D, Bird TD, Ghetti B, Nee LE, St George-Hyslop 
P, Pollen DA, Drachman DA (2000a) Familial Alzheimer's disease: site of mutation 
influences clinical phenotype. Ann Neurol 48:376-379. 
Lippa CF, Swearer JM, Kane KJ, Nochlin D, Bird TD, Ghetti B, Nee LE, St George-Hyslop 
P, Pollen DA, Drachman DA (2000b) Familial Alzheimer's disease: site of mutation 
influences clinical phenotype. Ann Neurol 48:376-379. 
Maril A, Simons JS, Weaver JJ, Schacter DL (2005) Graded recall success: an event-related 
fMRI comparison of tip of the tongue and feeling of knowing. NeuroImage 24:1130-1138. 
McDermott KB, Jones TC, Petersen SE, Lageman SK, Roediger HL, III (2000) Retrieval 
success is accompanied by enhanced activation in anterior prefrontal cortex during 
recognition memory: an event-related fMRI study. J Cogn Neurosci 12:965-976. 
Meltzer JA, Constable RT (2005) Activation of human hippocampal formation reflects 
success in both encoding and cued recall of paired associates. NeuroImage 24:384-397. 
Morris JC, Heyman A, Mohs RC, Hughes JP, van BG, Fillenbaum G, Mellits ED, Clark C 
(1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. 
Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39:1159-1165. 
Mueggler T, Sturchler-Pierrat C, Baumann D, Rausch M, Staufenbiel M, Rudin M (2002) 
Compromised Hemodynamic Response in Amyloid Precursor Protein Transgenic Mice. J 
Neurosci 22:7218-7224. 
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal 
L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985-
1992. 
Pietrini P, Dani A, Furey ML, Alexander GE, Freo U, Grady CL, Mentis MJ, Mangot D, 
Simon EW, Horwitz B, Haxby JV, Schapiro MB (1997) Low glucose metabolism during 
brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to 
dementia. Am J Psychiatry 154:1063-1069. 
Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and 
related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol 
Aging 12:295-312. 
Regard M, Strauss E, Knapp P (1982) Children's production on verbal and non-verbal fluency 
tasks. Perceptual and Motor Skills 55:839-844. 
The PSEN1 C410Y mutation and memory 
  83 
Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D 
(1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 
allele for apolipoprotein E. N Engl J Med 334:752-758. 
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy 
J (2005) Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging 
measurements of regional hypometabolism. Proc Natl Acad Sci U S A 102:8299-8302. 
Reiman EM, Chen KW, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, 
Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset 
Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States 
of America 101:284-289. 
Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, De SS, Convit A, 
Osborne D, Weaver A, Thibodeau SN (1998) Hippocampal volumes in cognitively normal 
persons at genetic risk for Alzheimer's disease. Ann Neurol 44:288-291. 
Ringman JM, az-Olavarrieta C, Rodriguez Y, Chavez M, Fairbanks L, Paz F, Varpetian A, 
Maldonado HC, ias-Islas MA, Murrell J, Ghetti B, Kawas C (2005) Neuropsychological 
function in nondemented carriers of presenilin-1 mutations. Neurology 65:552-558. 
Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, 
Holman K, Tsuda T, . (1995) Familial Alzheimer's disease in kindreds with missense 
mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 
376:775-778. 
Rosano C, Aizenstein HJ, Cochran JL, Saxton JA, De Kosky ST, Newman AB, Kuller LH, 
Lopez OL, Carter CS (2005) Event-related functional magnetic resonance imaging 
investigation of executive control in very old individuals with mild cognitive impairment. 
Biol Psychiatry 57:761-767. 
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. The 
American Journal Of Psychiatry 141:1356-1364. 
Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E (2002a) 
Differences in cerebral metabolic impairment between early and late onset types of 
Alzheimer's disease. J Neurol Sci 200:27-32. 
Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E (2002b) 
Differences in cerebral metabolic impairment between early and late onset types of 
Alzheimer's disease. J Neurol Sci 200:27-32. 
Schmidt CF, Degonda N, Luechinger R, Henke K, Boesiger P (2005) Sensitivity-encoded 
(SENSE) echo planar fMRI at 3T in the medial temporal lobe. Neuroimage 25:625-641. 
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, 
Holman K, . (1995) Cloning of a gene bearing missense mutations in early-onset familial 
Alzheimer's disease. Nature 375:754-760. 
Small GW, Ercoli LM, Silverman DHS, Huang SC, Komo S, Bookheimer SY, Lavretsky H, 
Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings 
JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral 
metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. 
The PSEN1 C410Y mutation and memory 
  84 
Proceedings of the National Academy of Sciences of the United States of America 97:6037-
6042. 
Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y (1999) Differential regional 
dysfunction of the hippocampal formation among elderly with memory decline and 
Alzheimer's disease. Ann Neurol 45:466-472. 
Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA 
(2000) Temporal Accrual of Complement Proteins in Amyloid Plaques in DownÆs 
Syndrome with AlzheimerÆs Disease. Am J Pathol 156:489-499. 
Stroop J (1935) Studies of interference in serial verbal reactions. Journal of Experimental 
Psychology 18:643-661. 
Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, gna-Bricarelli F, Scartezzini P, 
Bertolini S, Mann DM, Tabaton M, Gambetti P (1996) Presence of soluble amyloid beta-
peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2:93-95. 
Tewes U (1991) HAWIE-R. Hamburg-Wechsler Intelligenztest für Erwachsene Revision 
1991. Bern: Verlag Hans Huber. 
Tulving E (1985) Memory and Consciousness. Canadian Psychology-Psychologie 
Canadienne 26:1-12. 
 
 
 
The PSEN1 C410Y mutation and memory 
  85 
Supplementary information 
 
 
 
The PSEN1 C410Y mutation and memory 
  86 
 
The PSEN1 C410Y mutation and memory 
  87 
 
The PSEN1 C410Y mutation and memory 
  88 
 
The PSEN1 C410Y mutation and memory 
  89 
 
The PSEN1 C410Y mutation and memory 
  90 
 
The PSEN1 C410Y mutation and memory 
  91 
 
 
 
 
 
 
 
General discussion 
  92 
4. General Discussion 
 
4.1. Aims of the present studies and some methodological remarks 
 
The two studies presented here sought to detect genetic influences on memory capacity, 
memory-related brain activity, and neuroanatomy. We choose to investigate two AD-related 
genes, because they have already been implicated in memory functions in studies with MCI, 
prodromal AD, and AD patients. Moreover, the genetic variation in these genes has been 
associated with specific physiological effects at the cellular level and their impact has been 
described in distinct brain regions. First, we examined the apolipoprotein E gene, of which the 
ε4 allele is a known genetic riskfactor for AD. It exerts detrimental effects on memory 
performance, brain metabolism, and memory-related brain activity in middle-aged and elderly 
subjects, probably through its relation to the neuropathological hallmarks of the disease. 
Second, we examined the presenilin 1 gene, which is directly linked to the disease because of 
its causative nature. It is, however, conceivable that both genes might also play a role in 
normal interindividual memory variability, independently of their strong coupling to the 
Alzheimer’s Disease causing neuropathological events.  
 
To address our hypotheses (please see chapter 2) we combined genetic analyses, 
neuroimaging, quantitative neuropsychological assessments, and methods from experimental 
psychology. At the core of both studies was a memory-paradigm that included the learning 
and retrieval of face-profession associations and single faces. This paradigm had been chosen 
primarily to activate medial temporal lobe structures, including the hippocampus. These 
structures have been implicated in relational memory (Cohen and Eichenbaum, 1993; 
Gabrieli, 1998; Henke et al., 1997; Henke et al., 1999b). They are the first to be affected by 
neurofibrillary tangle formation, one of the hallmarks of AD (Braak and Braak, 1996; 
Delacourte et al., 1999). Neurofibrillary tangle formation and amyloid plaque deposition (the 
other neuropathologic hallmark of AD) lead to neural dysfunction and neural death, hence 
evoking memory decline at the beginning of the disease and a subsequent total memory loss 
in later stages of the disease. Our group showed in preceding studies that the tasks adopted 
here reliably activated the hippocampal formation (Degonda et al., 2005; Henke et al., 2003). 
For the present studies we adapted and extended past memory paradigms. Because we 
expected to detect only small genotype-induced changes in memory activity, the learning 
procedure was repeated three times. The repeated learning procedure allowed us to measure 
subtle repetition effects and turned out to be a great gain in the APOE study, where the most 
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significant genotype-induced brain activity changes could be tackled during repeated learning. 
Moreover, a working memory task and an attentional task were added, allowing us to 
investigate whether genotype induced effects on memory function were specific to episodic 
and semantic memory, or whether they also encompassed additional cognitive functions, like 
working memory or attentional abilities. 
 
The investigation of genetic traits on memory functions imposes a quasi-experimental design. 
This means, that the genetic variation between subjects defines the independent variable, 
while the various measured memory functions that were modulated by the genotype define 
the dependent variable. Quasi-experimental designs imply the disadvantage of confounding 
variables. These can bias the measured effect on the independent variable. The contribution of 
single genes to the response characteristics of brain structures is presumably small. Typically 
large effects of age, gender and IQ as well as environmental factors such as illness, injury or 
substance abuse on phenotypic variance obscure the small potential gene effects. We therefore 
had to carefully match our samples in both studies for confounding variables known to have a 
modulatory effect on memory capacity, memory-related brain activity and neuroanatomy. 
Because our imaging protocol involved performance of a task, groups were also matched for 
level of performance. This is a crucial point because task performance and neural responses 
are tightly linked, and systematic differences in performance between genotype groups could 
have occluded a true gene effect.  The careful matching of our subjects ensured that resulting 
differences between genotype groups (APOE study) or between mutation carriers and control 
subjects (PSEN1 study) could directly be related to the APOE genotype or the PSEN1 C410Y 
mutation, respectively.  
  
4.2. Beneficial effects of the APOE ε4 allele on memory 
 
In the APOE study we first examined associations between allelic variations in the APOE 
gene and memory performance in a sample of 340 healthy young adults. The ε4 allele, a 
genetic risk factor for the development of late-onset Alzheimer’s Disease (Saunders et al., 
1993), was associated with a significantly better performance in recalling words after a delay 
of 5 minutes, as compared to the ε2 and ε3 alleles. So far, most studies investigating effects of 
APOE on biological processes were conducted either in middle-aged to elderly nondemented 
healthy subjects or in prodromal AD patients. These studies suggested a detrimental role of 
APOE4 on memory performance (Baxter et al., 2003; Bondi et al., 1995; Hyman et al., 1996), 
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executive functions (Rosen et al., 2005), attention (Greenwood et al., 2000), memory-related 
brain activity (Bondi et al., 2005; Bookheimer et al., 2000), and brain glucose metabolism 
(Reiman et al., 2002b). Our finding of better memory in APOE4 carriers was, therefore, 
somewhat intriguing. However, it is conceivable, that APOE-related alterations in cerebral 
physiology may exist even from young age. Studies with very young subjects or even children 
documented effects of the APOE genotype on cognitive performance in type I diabetes 
(Ferguson et al., 2003), lipid metabolism (Srinivasan et al., 2001), blood pressure (Katsuya et 
al., 2002), atherosclerosis (Hixson, 1991), ischaemic heart disease (van Bockxmeer and 
Mamotte, 1992), and myocardial infarction (Brscic et al., 2000). Moreover, evidence from 
studies with young mice indicates, that the APOE genotype affects stress response and spatial 
memory (Zhou et al., 1998), and regulates synaptic plasticity and long term potentiation in the 
hippocampus (Valastro et al., 2001). 
 In a second step, we examined 34 subjects of the large sample group with fMRI to 
investigate, on a neurophysiologic level, the advantageous APOE4-effects on memory that we 
had found in the large sample. The APOE4 allele was associated with less learning- and 
retrieval-related brain activity compared to APOE2 and APOE3. The smaller hippocampal 
and neocortical activity was found at comparable performance levels in the memory tasks 
between the three genotype groups (i.e. APOE ε2/ε3, ε3/ε3, and ε3/ε4). Also, 
neuropsychological test performance and brain volumes did not significantly differ between 
groups. Therefore, the measured signal differences between the three APOE groups were 
neither related to differences in cognition nor to brain morphology alterations, but reflected an 
unbiased APOE genotype effect on memory-related neurophysiologic functions. The most 
intriguing finding, however, was revealed during repeated learning. While the APOE4 carriers 
decreased learning-related hippocampal and neocortical activity, the APOE4 noncarriers 
increased their learning-related activity. Moreover, decreasing learning-related activity 
denoted the good performers in the APOE4 group, while increasing learning-related activity 
denoted the good performers in the APOE2 group. We did not find a significant correlation of 
medial temporal activity slopes with the shortening of reaction latencies during repeated 
learning in any APOE group. Therefore the genotype-dependent brain activity differences 
likely reflected a differential neurophysiology underlying episodic memory and not another 
form of memory (i.e. priming) which was simultaneously active during the learning runs.  
To our knowledge this is the first study that investigated APOE genotype effects on 
normal human memory variability using functional magnetic resonance imaging. The results 
suggest that the APOE4 allele is associated with a better memory and a more economic use of 
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memory-related neural resources in young and healthy subjects. Our findings of an 
advantageous effect of APOE4 early in life add to a variety of studies showing beneficial 
effects of APOE4 in young humans (Hubacek et al., 2001; Ravaja et al., 1997; Yu et al., 
2000; Zetterberg et al., 2002) and young animals (Kitamura et al., 2004; Ohkubo et al., 2001). 
Nevertheless, the beneficial effect of the APOE4 allele stands in contrast to most studies 
reporting an association of APOE4 with detrimental effects on cognition and brain functions 
in middle-aged and elderly human subjects. Although our findings are, with high probability, 
not related to AD pathology, it is still unclear whether the brains of young adults are 
completely devoid of such depositions 30-50 years prior to the statistical onset of the disease. 
A neuropathological study examined 105 necropsy cases which showed no signs of dementia. 
Abnormally high brain ß-amyloid levels were reported for ε4 carriers as young as 40 years of 
age, suggesting that APOE4 carriers begin to accumulate ß-amyloid earlier in life than non-
carriers. However, neurofibrillary tangle formation is rarely occurring in the brains of 20-30 
years olds (Ghebremedhin et al., 1998), whereas brain amyloid deposition has been found 
irrespective of APOE genotype in young subjects (Morishima-Kawashima et al., 2000). 
Therefore, it is unlikely that early neuropathological changes underlie our fMRI results.  
 
Our study was not able to answer the question, whether the beneficial effect of APOE4 on 
memory in young adulthood and the detrimental effects in later stages of life are two distinct 
processes running parallely along each other, or alternatively, whether there might be a 
transition point between 20 and 40 years of age, where initial beneficial effects start to turn 
into lethality. Possibly, this question can not be answered by means of neuroimaging alone, 
but must be investigated at the cellular level. However, Reiman et al. (2004) used FDG PET 
in cognitively healthy young (20-39 years) APOE4 carriers to detect earliest AD-pathology 
induced changes in glucose metabolism. They found abnormally low rates of glucose 
metabolism bilaterally in the posterior cingulated, parietal, temporal, and prefrontal cortex, 
brain regions known to be affected by neuropathological changes in AD. These results 
suggest that glucose metabolism could be the consequence of a very limited histopathology 
that may or may not be present in cognitively normal young adults. However, the authors 
argue that, alternatively, this hypometabolism could also reflect abnormalities in prenatal or 
early postnatal neurological development.  
A longitudinal follow-up of our subjects in the next ten years would render valuable 
information about how memory-related brain activity and memory performance is modulated 
by APOE4 during a period in witch presumably AD-related neuropathologic deposits start to 
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accumulate. Hopefully one could detect time windows in which changes from smaller (more 
economic) brain activity to brain activity with greater magnitude and extent (compensatory 
activity) are observable, hence determining earliest preclinical signs of AD. 
 
Although our study delivers first insights into the involvement of the APOE gene in normal 
human memory variability on the behavioural and neurophysiological level, future studies 
need to investigate what the underlying cellular mechanisms are. Profound knowledge of the 
effects of APOE isoforms on memory mechanisms will not only broaden basic knowledge 
about memory function in general, but could also open the way for a detection of AD 30-50 
years prior to its clinical onset. 
 
 
4.3. Influence of the PSEN1 C410Y mutation on memory – earliest preclinical signs of   
       AD  
 
In this study we investigated five members of a family with FAD. Two of the family 
members, a young man (20 years old) and a middle-aged woman (45 years old) carried the 
C410Y mutation on the PSEN1 gene. This mutation is transmitted in an autosomal dominant 
manner and leads to familial Alzheimer’s Disease with a reported age of onset of 48 years 
(Alzheimer's Disease Collaborative Group, 1995).  
As yet the earliest neuropsychological features of FAD have been found in individuals 
at risk of autosomal dominant FAD within one decade prior to the clinical onset of the disease 
(Fox et al., 1998; Ringman et al., 2005). Attempts to detect early signs of the disease have 
also been made by the use of neuroimaging techniques (Bookheimer et al., 2000; Gregory et 
al., 2005; Reiman et al., 2004; Reiman et al., 1996; Rossor et al., 1996; Small et al., 1995). 
AD-related neuropathologic depositions start 15-30 years prior to the onset of the disease 
(Davies et al., 1988; Rumble et al., 1989) and subsequently lead to neuronal loss. It is 
therefore conceivable that neural dysfunction might be reflected in the measured brain signals 
decades prior to the clinical manifestation.  
Here we were able to show that memory deficits can be detected as long as 30 years prior to 
the onset of FAD. The two PSEN1 C410Y mutation carriers examined in this study showed 
selective episodic memory impairments in neuropsychological memory tests. The young 
mutation carrier presented with visual episodic memory impairments that exceeded two 
standard deviations as compared to an age- and education-matched control population. In all 
other tests the young mutation carrier performed well and showed scores of high intelligence. 
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The memory impairments in the middle-aged mutation carrier were further progressed, 
encompassing both verbal and visual memory. These data suggest that the middle-aged  
mutation carrier was suffering from mnestic mild cognitive impairment (Petersen et al., 2001) 
at the time of examination.  
We also compared both mutation carriers to family members without the mutation. A 
young mutation non-carrier showed low neuropsychological scores on a wide range of 
cognitive functions and a low intelligence. Most likely the low scores in this subject can be 
attributed to her low inherent cognitive capacity. The middle-aged mutation non-carrier only 
showed a low performance in tests of intelligence. These results emphasize the selectivity of 
the episodic memory impairments in the mutation carriers and relate them to the PSEN1 
C410Y mutation. However, the selective episodic memory impairments might not reflect an 
influence of the mutation on normal neurophysiologic function, but rather reflect a 
detrimental effect of PSEN1 through AD-related neuropathology. The selective memory 
impairment in the young mutation carrier is most likely attributable to neural dysfunction in 
the MTL, evoked by early neurofibrillary tangle formation (Braak and Braak, 1996) and 
amyloid plaque deposition. Neurofibrillary tangle formation starts in the entorhinal cortex 
(Braak and Braak, 1996), thereby making the MTL the most vulnerable brain area for early 
preclinical memory impairments.  
MTL dysfunction in our young mutation carrier is most likely explainable through the 
direct effects of the presenilin 1 protein on tau phosphorylation or through an indirect effect 
on tau-pathology (Boutajangout et al., 2002; Takashima et al., 1998). PSEN1 mutations have 
been associated with significant increases of plasma Aß42 levels together with a massive 
deposition of Aß42 in the brain (Iwatsubo, 1998; Lemere et al., 1996). The accumulation of 
Abeta appears to be an early and initiating event that triggers a series of downstream 
processes including misprocessing of the tau protein (St George-Hyslop and Petit, 2005). It is 
conceivable that our young mutation carrier suffers from early neuropathologic deposits, 
because the genetic defect is present since birth. This notion is supported by studies of 
patients with Down’s syndrome10 where deposition of Aß 1-42 has been observed as early as 
in the third decade (Stoltzner et al., 2000; Teller et al., 1996) of life.  
                                                      
10 Down’s syndrom (trisomy 21) is a genetic disorder which is characterized by the presence of a third chromosome 21 
(including the Aß-amyloid precursor protein gene). Subjects with Down’s syndrome over the age of 40 years show AD-like 
neuropathological and neurochemical abnormalities post-mortem. In these patients, cognitive dysfunctions and dementia 
increase with aging, and more than 75% over 60 are demented (Lai and Williams, 1989). Therefore, Down’s Syndrome is a 
unique human model with which preclinical stages of AD and the transition to dementia can be studied (Holland and Oliver, 
1995). 
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Detrimental effects of the PSEN1 C410Y mutation were also reflected in brain signal 
measures with fMRI. Here both mutation carriers exhibited significantly altered patterns of 
memory-related brain activity as compared to the control group and the family members 
without the mutation. The young mutation carrier showed enhanced brain activity in the 
hippocampus and a memory-related network during learning and retrieval of face-profession 
associations and single faces. This amplified activity was almost only attributable to 
structures of the left hemisphere, and appeared at a comparable performance level between 
the young mutation carrier and the control group in the fMRI memory tasks. The most likely 
explanation for the task-related activity enhancements in the MTL and the neocortical regions 
is a compensatory reponse to accumulating AD pathology. The neuropsychology data suggest 
that the young mutation carrier is suffering from right-lateralized neural dysfunction in the 
MTL and neocortical areas because he showed selective visual memory impairments in 
nonverbal tasks. It is, therefore, likely that the left hemisphere has to ‘work harder’ to 
overcome memory deficits which are the consequence of the right-lateralized AD-related 
neuropathology. These results are in line with studies that showed task-related brain signal 
amplifications in the MTL and neocortical structures in elderly non-demented AD risk allele 
(APOE4) carriers (Bondi et al., 2005; Bookheimer et al., 2000). The ‘compensatory 
hypothesis’ proposed in these studies suggests that after an initial decline in memory 
proficiency following damage to MTL structures, patients in the preclinical stage of AD are 
able to effectively recruit compensatory brain resources to halt or slow further memory 
decline for a period of time.  
The middle-aged mutation carrier, on the other hand, showed a low performance in the 
face recognition task and exhibited almost only reduced activity in the MTL and in memory-
related structures while performing the memory-tasks. Decreased task-induced brain activity 
in early stage AD patients has been found as well as compensatory amplification of task-
induced brain activity in MCI patients (Buckner et al., 2000; Dickerson et al., 2004; Kato et 
al., 2001; Rosano et al., 2005; Small et al., 1999). In our subject, the decreased activity most 
likely reflects gross neural dysfunction that is a consequence of the further progressed 
accumulation of amyloid deposits and neurofibrillary tangle formation. The degree of neural 
dysfunction in FAD is much more extensive than in the sporadic AD cases, and might 
therefore have extensively diminished still functioning neural ensembles that would have 
allowed a compensatory response in the middle-aged mutation carrier. 
Both mutation carriers could be clearly differentiated from the control groups and the 
family members without the mutation in terms of the observed memory-related brain activity 
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patterns. While the family members without the mutation showed a balanced pattern of 
memory-related activity (i.e. they showed areas of increased as well as areas of reduced 
activity in comparison to the control group) this was not the case for the young and the 
middle-aged mutation carriers. They either showed enhanced or reduced memory-related 
brain activity. This suggests that the brain activity alterations in the mutation carriers were 
selectively modulated by the PSEN1 mutation. Moreover, the effect of the mutation was only 
evident in tasks of episodic memory. In the working memory experiment, each and every 
family member showed enhanced brain activity as compared to the control group. This 
‘family pattern’ of enhanced activity occurred independently of genotype, hence confirming 
the role of PSEN1 in episodic memory function. 
Interestingly, we did not find alterations in brain morphology induced by the PSEN1 
mutation. It has been shown, that FAD-causing mutations on the PSEN1 gene and the APP 
gene can influence the degree and the regional pattern of atrophy (Gregory et al., 2005). 
Moreover these mutations were associated with greater medial temporal lobe atrophy in cases 
with FAD than in sporadic AD cases, suggesting that mutations affecting Aß metabolism 
selectively increase hippocampal degeneration. Also, cases with mutations in the PSEN1 gene 
demonstrated additional increased frontotemporal atrophy. In our young mutation carrier 
early neuropathological events might have led to neural dysfunction (as reflected in memory 
performance and memory-related brain activity), but not yet to neural death. Therefore, 
morphological changes in the young mutation carrier would have been unlikely. In the 
middle-aged mutation carrier, however, progressed accumulation of amyloid plaques and 
neurofibrillary tangle formation might have led to neuronal loss. Possibly, neuronal death in 
that subject was only of a small extent and therefore did not lead to detectable gross 
morphological changes before the clinical onset of FAD. 
Taken together, these results suggest that early preclinical signs of AD are detectable 
three decades before the onset of the disease on the behavioral and the neural level. However, 
our results must remain tentative because they are based on a single case. Therefore we 
cannot generalize findings to other PSEN1 mutations or to sporadic cases with probable AD. 
Still, one can be confident that with a future improvement of fMRI image quality through 
higher magnetic fields and with the application of sensitive episodic memory tasks tailored to 
hippocampal function subtle changes in MTL-function might be detectable decades before the 
onset of AD, possibly even in sporadic cases. The preclinical detection of earliest markers for 
AD is the prerequisite for a hopefully effective preventive treatment of the disease, and 
therefore remains a core issue in future AD research. 
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5. Conclusions 
 
The recent completion of the human genome sequence provides unprecedented opportunities 
to explore the genetic basis of individual differences in complex behaviours and the 
vulnerability to neuropsychiatric disorders. Linkage and association analyses were the 
traditional methods of choice for finding susceptibility genes for complex disorders. 
However, they did not provide information about the mechanisms by which such genes 
modulate normal physiologic functions or increase biological risks for neuropsychiatric 
diseases. Traditionally, the impact of genetic polymorphisms has been examined on the 
behavioural level using personality questionnaires and neuropsychological batteries. Because 
of the individual variability and subjectivity of such behavioural measures it was necessary to 
use very large samples (i.e. several hundred subjects) to identify even small gene effects (Glatt 
and Freimer, 2002). In such studies potential gene effects on the task-related neural substrates 
might have been obscured, for example, because of the interindividual applied alternative task 
strategies in the behavioral tests. Functional genetic polymorphism may have a more robust 
impact on the neural level than on the behavioural level and therefore neural responses related 
to specific cognitive and emotional processes may be more objectively measurable by means 
of non-invasive neuroimaging techniques like fMRI. In comparison to pure behavioural 
assessments, neuroimaging techniques require considerably fewer subjects to identify 
significant gene effects on the response characteristics of the brain and allow the investigation 
of the specificity of gene effects by examining their influence on multiple functional neural 
systems in a single subject. Due to these advantages neuroimaging emerged as the method of 
choice for the in vivo study of functional genetic variations. 
The results of the two studies presented here underscore the power of functional 
magnetic resonance imaging to identify functional polymorphisms in genes that are likely 
important either for normal human memory or for pathological memory alterations in the 
context of a neuropsychiatric disease (i.e. Alzheimer’s Disease). They also show the 
advantage of a systems level approach by integrating genetic information with a phenotypic 
trait (i.e. cognitive, neurophysiological, and neuroanatomical measures) to successfully 
determine the influence of genes on brain function.  
We used functional and structural MRI to determine the impact of the APOE gene and 
the PSEN1 gene on memory performance, memory-related brain activity and neuroanatomy. 
We were able to show, that APOE4, an allele associated with detrimental effects on several 
biological processes and with an increased risk for the development of AD, exerted beneficial  
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effects on memory function in young and healthy adults. These effects were likely not related 
to AD-neuropathology, and therefore suggest that the APOE gene plays an important role in 
normal memory function, independent of its relation to pathological mechanisms of AD.  
The mutation on the PSEN1 gene, on the other hand, was associated with detrimental 
effects on memory performance and memory-related brain activity in a young mutation 
carrier, most likely suggesting that PSEN1 mutation effects on memory were mediated 
through the neuropathology of AD. Because PSEN1 mutation carriers bear the mutation since 
birth, it is likely that AD-related neuropathological events take place already in the early years 
of life. It was therefore almost impossible to measure an AD pathology independent effect of 
the PSEN1 mutation on normal memory function in this young subject.  
Nevertheless, both studies provide useful insights into how genetic variants modulate 
memory functions on the neural and the behavioural level. Our results complete findings from 
previous studies that reported an influence of polymorphisms of the 5HT-2a receptor 
encoding gene, the PRNP gene, and the BDNF gene on normal human memory function 
(deQuervain et al., 2003; Papassotiropoulos et al., 2005; Egan et al., 2003; Hariri et al., 2003) 
Moreover, our findings might be implicated in future AD research aiming at the preclinical 
detection of earliest markers of the disease.  
The genetic basis of human cognition, behaviour, and psychiatric illnesses is of a high 
complexity with each gene exerting only a small effect. A single gene can affect multiple 
processes, multiple genes can impact on a single process, and multiple cognitive processes are 
intercorrelated. The association between a genotype and a variation in a cognitive function 
can not be taken as a proof for the impact of the genetic variant on brain function, because 
many confounding factors could account for the association. To overcome this problem, we 
thoroughly minimized potentially confounding factors in our studies and accounted for 
possible genetic heterogeneity between subjects. Therefore, one can be confident that the 
results in our studies reflect true genetic effects on cognition and brain function. 
 
So far, the majority of studies that used neuroimaging to investigate the genetic basis of 
memory reported only effects of single genetic polymorphisms. Future studies need to 
investigate the functional interactions between multiple gene variants (gene clusters), the 
environment, and their collective impact on brain function. Also, it is conceivable that 
molecular mechanisms underlying genetic influences on neural information processing might 
be detected.  
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Finally, to determine a comprehensive genetic basis of human cognition the quest for 
candidate genes must be extended to other important human cognitive domains, including 
basic aspects of language, attention or visual processing. 
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